Modified PEDV spike protein
Modifying the PEDV spike protein's amino acid sequence at the S1/S2 cleavage site enhances vaccine production and efficacy, addressing the limitations of existing vaccines by providing robust protection against PEDV strains.
Patent Information
- Application Number
- JP2023021428
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-28
- Filing Date
- 2023-02-15
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-09-18
AI Technical Summary
Existing vaccines for Porcine Epidemic Diarrhea Virus (PEDV) do not effectively address the production method improvements and protection against newly emerging strains, particularly those administered via the mucosal route.
Modification of the PEDV spike protein by altering the amino acid sequence at the S1/S2 cleavage site, specifically the RSX 1 IEDX 2 X 3 motif, to enhance production levels and efficacy of vector-based vaccines, including mutations at specific positions for genotypes 2a and 2b.
The modified spike protein vaccines demonstrate increased production levels and provide effective protection against PEDV infection, reducing mortality and clinical symptoms in piglets.
Smart Images

Figure 0007587612000003 
Figure 0007587612000004 
Figure 0007587612000001
Abstract
Description
[Technical field]
[0001] SEQUENCE LISTING This application contains a sequence listing in accordance with 37 CFR 1.821-1.825. The sequence listing accompanying this application is incorporated herein by reference in its entirety. (Technical field) The present invention relates to a modified PEDV (Porcine Epidemic Diarrhea Virus) spike (S) protein. The modification results in an improved method for the production of PEDV vaccines. Furthermore, vaccines containing the modified spike protein are effective as vaccines and provide protection against PEDV infection or challenge. Due to high mortality rates (up to 100%) in piglets under 10 days of age, the disease is an economic problem for, for example, the US swine industry. [Background technology]
[0002] Porcine epidemic diarrhea virus is an enveloped, positive-sense, single-stranded RNA virus that causes acute diarrhea, vomiting, and dehydration in pigs. In pigs aged 3 weeks or younger, clinical signs (including acute watery diarrhea, vomiting, and dehydration) are observed immediately 24 hours after PEDV infection, resulting in up to 100% mortality. In addition, gross and histological changes in the intestine of PEDV-infected animals can result in gross pathological lesions in the small intestine. PEDV was first identified in Europe, but is becoming increasingly problematic in many Asian countries, including Korea, China, Japan, the Philippines, and Thailand. Since 2013, PEDV has appeared in the United States, and the economic impact of PEDV infection is already significant. There is therefore a continuing need to develop vaccines that can protect pigs against PEDV-associated disease. In this regard, there is a particular need for vaccines that are effective against emerging PEDV strains that can be administered via mucosal routes (oral or intranasal). Although only one PEDV serotype has been reported, phylogenetic studies of the S gene indicate that PEDV can be genetically classified into two groups: genogroup 1 (G1; classical) and genogroup 2 (G2; epidemic or pandemic). Each genogroup can be further divided into subgroups (1a and 1b; 2a and 2b). G1a includes the prototype PEDV strain CV777, vaccine strains and other cell culture adapted strains, while G1b includes novel variants that were first identified in China and later in the United States, Korea and Europe. G2 includes global field isolates, which are further clustered into 2a and 2b subgroups (G2a and G2b), responsible for previous local epidemic outbreaks in Asia and recent pandemic outbreaks in North America and Asia, respectively.
[0003] PEDV is an alphacoronavirus ( Alphacoronavirus PEDV is a member of the coronavirus subfamily of the genus Coronaviridae. PEDV is an enveloped virus with a positive-sense, single-stranded RNA genome of approximately 28 kb with a 5' cap and a 3' polyadenylated tail (Pensaert and De Bouck P. 1978). The genome contains a 5' untranslated region (UTR), a 3' UTR, and at least seven open reading frames (ORFs). The ORFs encode four structural proteins (spike (S), envelope (E), membrane (M), and nucleocapsid (N)) and three nonstructural proteins (replicases 1a and 1b, and ORF3), which are arranged in the genome in the following order: 5'-replicase (1a / 1b)-S-ORF3-EMN-3' (Oldham J. 1972; and Bridgen et al. 1993). PEDV S protein is a type I glycoprotein, and the S protein of (G2b PEDV) contains 1,383 amino acids (aa). Based on its homology with S proteins of other coronaviruses, the S protein can be divided into S1 (e.g., 1-789 aa) and S2 (e.g., 790-1,383 aa) domains. Coronavirus S protein is a surface antigen, which plays a role in regulating the interaction with host cell receptor glycoproteins to mediate viral entry and stimulating the induction of neutralizing antibodies in the natural host. Therefore, the S glycoprotein is a major target for the development of an effective vaccine against PEDV.
[0004] Madu et al. (J. Virol., 2009, 3 (15), p. 7411-7421) describe two single mutations (L803A and L8-4A) in the spike protein of SARS (Severe Acute Respiratory Syndrome) and show that each of the single mutations has an effect on membrane fusion activity. Furthermore, Ujike & Taguchi (Viruses, 2015, 7, 1700-1725) describe that mutations in the tyrosine-dependent YXXI signal showed enhanced surface expression. Shirato et al. (Virus Res., 2011, 161 (2):188-93) describe that the H1381R mutation in the KxHxx motif of PEDV results in transport of the spike protein to the plasma membrane. However, none of the above documents discloses which modifications in the spike protein may improve the production process of a PEDV vaccine and whether such a produced vaccine with modifications in the spike protein would still be suitable as a vaccine and provide protection against PEDV infection or challenge. Summary of the Invention [Problem to be solved by the invention]
[0005] However, none of the above documents discloses which modifications in the spike protein may improve the production process of a PEDV vaccine and whether such a produced vaccine with modifications in the spike protein would still be suitable as a vaccine and provide protection against PEDV infection or challenge. The solution to the above technical problem is achieved by the descriptions and embodiments characterized in the claims. [Means for solving the problem]
[0006] Therefore, the invention in its various aspects is embodied in accordance with the claims. In this regard, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1), (I) X2 is an amino acid residue other than a leucine residue and X3 is a leucine residue; or (II) X2 is a leucine residue and X3 is an amino acid residue other than a leucine residue; or (III) X2 is an amino acid residue other than a leucine residue, and X3 is an amino acid residue other than a leucine residue. In particular, R in the sequence RSX1IEDX2X3 (SEQ ID NO:1), as well as R in any of SEQ ID NOs:4, 5, 21-25 and 31-35, is a conserved arginine residue located C-terminally towards the S1 / S2 cleavage site. Said R is also referred to hereinafter as "the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein". More particularly, said R is an arginine residue flanking the N-terminus of the fusion peptide of said PEDV S protein. Said fusion protein generally begins with the sequence SXIED. In particular, said fusion peptide is within the S2 subunit of the PEDV S protein. [Brief description of the drawings]
[0007] [Figure 1]Subcellular localization of target proteins (PEDV-S2b-wt and PEDV-S2b-mut) in PK13 cells. The top three panels show that the expression of spike protein delivered from the EHV1-PEDV-S2b-wt recombinant vector is mainly localized in the cytoplasm, whereas PEDV-S expressed from EHV1-PEDV-S2b-mut is mainly localized in the plasma membrane, as shown in the bottom three panels. [Diagram 2] Comparison of the growth in Vero cells of the vectors described in Example 3 (CDV-PEDV-spike-MUT (=CDV-PEDV-spike mut) and CDV-PEDV-spike-WT (=CDV-PEDV-spike WT)). The upper curve relates to CDV-PEDV-spike mut and the lower curve to CDV-PEDV-spike WT. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] Before describing the features of the present invention, the following should be noted. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, a reference to "an antigen" includes a plurality of antigens, a reference to a "virus" is a reference to one or more viruses and equivalents thereof known to those of skill in the art, and so forth. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodology reported in the publications that may be used in connection with the present invention. Nothing in the foregoing should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. The present invention is based on the surprising discovery that mutations in the amino acid sequence of the PEDV spike protein are sufficient to increase the production level of a vector-based PEDV vaccine. Furthermore, animal studies have shown that PEDV vector-based vaccines with such modified spike proteins are effective and can provide protection or protect against PEDV infection or challenge. Thus, the present invention solves the problems inherent in the prior art and provides a clear advance in the state of the art.
[0009] In this regard, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1), (I) X2 is an amino acid residue other than a leucine residue and X3 is a leucine residue; or (II) X2 is a leucine residue and X3 is an amino acid residue other than a leucine residue; or (III) X2 is an amino acid residue other than a leucine residue, and X3 is an amino acid residue other than a leucine residue. In particular, R in the sequence RSX1IEDX2X3 (SEQ ID NO:1), as well as R in any of SEQ ID NOs:4, 5, 21-25 and 31-35, is a conserved arginine residue located C-terminally towards the S1 / S2 cleavage site. Said R is also referred to hereinafter as "the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein". More particularly, said R is an arginine residue flanking the N-terminus of the fusion peptide of said PEDV S protein. Said fusion protein generally begins with the sequence SXIED. In particular, said fusion peptide is within the S2 subunit of the PEDV S protein.
[0010] The sequence RSX1IEDX2X3 (SEQ ID NO: 1) is therefore also understood to be in particular the sequence of the fusion domain of said PEDV S protein. More specifically, in the context of the sequence RSX1IEDX2X3 (SEQ ID NO: 1), as well as in the context of any of SEQ ID NOs: 4, 5, 21-25, and 31-35, R associates with the conserved arginine residue at amino acid position 894 when the PEDV S protein is a genotype 2a (G2a) PEDV S protein, or R associates with the conserved arginine residue at amino acid position 891 when the PEDV S protein is a genotype 2b (G2b) PEDV S protein. Thus, with respect to amino acid positions, the statement "the conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein" is understood to be equivalent to "R is the arginine residue at amino acid position 894 when the PEDV S protein is a genotype 2a (G2a) PEDV S protein, and the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein, preferably the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:39, or R is the arginine residue at amino acid position 891 when the PEDV S protein is a genotype 2b (G2b) PEDV S protein, and the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein, preferably the amino acid sequence of SEQ ID NO:3." In general, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1), wherein R is a conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, and X1 can be any amino acid residue; and (I) X2 is an amino acid residue other than a leucine residue and X3 is a leucine residue; or (II) X2 is a leucine residue and X3 is an amino acid residue other than a leucine residue; or (III) X2 is an amino acid residue other than a leucine residue, and X3 is an amino acid residue other than a leucine residue.
[0011] The term "nucleic acid molecule" refers to a polynucleotide, which includes DNA molecules, RNA molecules, cDNA molecules or derivatives. The term encompasses single-stranded polynucleotides as well as double-stranded polynucleotides. Preferably, the term refers to single-stranded RNA or double-stranded cDNA. The nucleic acids of the present invention encompass isolated polynucleotides (i.e., isolated from their natural environment) and genetically modified forms. Furthermore, chemically modified polynucleotides are also included, which include naturally occurring modified polynucleotides (e.g., glycosylated or methylated polynucleotides) or artificially modified polynucleotides (e.g., biotinylated polynucleotides). Furthermore, it should be understood that the spike protein referred to above can be encoded by a number of polynucleotides due to the degenerate genetic code. Moreover, the terms "nucleic acid" and "polynucleotide" are interchangeable and refer to any nucleic acid. The terms "nucleic acid" and "polynucleotide" also specifically include nucleic acids that contain bases other than the five biologically occurring bases (adenine, guanine, thymidine, cytosine and uracil).
[0012] The term "PEDV" is well known to those skilled in the art. PEDV means porcine epidemic diarrhea virus, which is a member of the coronavirus subfamily of the alphacoronavirus genus. The term "spike" refers to a specific protein of PEDV that is well known to those skilled in the art. The spike protein is the main inducer of antibody and protective immune responses. In addition, the spike protein also plays a major role in the cell entry program of PEDV by binding to the cellular receptor of the host cell and by mediating virus-cell membrane fusion with the host cell. Furthermore, it is understood that the term "PEDV S protein" is equivalent to the abbreviation "PEDV S" (often used in the context of PEDV). The terms "protein", "amino acid" and "polypeptide" can be used interchangeably. The term "protein" refers to an amino acid (aa) sequence, including naturally occurring amino acids as well as derivatives thereof. Naturally occurring amino acids or genetically encoded amino acid residues, respectively, are well known in the art and are described in standard biochemistry textbooks. Within an amino acid sequence, the amino acids are linked by peptide bonds. Furthermore, the terminus of an amino acid sequence refers to the carboxyl terminus (C-terminus) and the amino terminus (N-terminus). The term "protein" encompasses essentially purified proteins or protein preparations that otherwise contain other proteins. Furthermore, the term also relates to protein fragments. Furthermore, the above also includes chemically modified proteins. Such modifications may be artificial or naturally occurring (e.g., phosphorylation, glycosylation, myristoylation, etc.).
[0013] In the context of the present invention, the phrase "R is a conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein" is understood to be equivalent to "R is a conserved arginine residue located C-terminally towards the S1 / S2 cleavage site of the PEDV S protein" or "R is a conserved arginine residue flanking the N-terminal fusion peptide of the PEDV S protein", respectively. The phrase "N-terminally flanking the fusion peptide" is understood to be equivalent to "N-terminally flanking the fusion peptide sequence". The sequence RSX1IEDX2X3 (SEQ ID NO:1) should be understood as follows: -R is a conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, -S is the amino acid residue serine, -X1 is any of the 20 genetically encoded amino acid residues, -I is an isoleucine residue, -E is a glutamic acid residue, -D is an aspartic acid residue, -X2 is variable. X2 has two conditions. X2 can be an amino acid residue other than leucine (condition 1), which means that X2 can be any genetically encoded amino acid residue except for a leucine residue. Alternatively, X2 can be a leucine residue (condition 2). -X3 is variable. X3 has two conditions: X3 can be an amino acid residue other than leucine (condition 1), which means that X3 can be any genetically encoded amino acid residue except for a leucine residue. Alternatively, X3 can be a leucine residue (condition 2).
[0014] Thus, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) Spike (S) protein comprising: a) the amino acid sequence RSX1IEDLX2 (SEQ ID NO:21), where R is the conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, X1 can be any amino acid residue, and X2 is an amino acid residue other than a leucine residue; or b) the amino acid sequence RSX1IEDX2L (SEQ ID NO: 22), in which R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein, X1 can be any amino acid residue, and X2 is an amino acid residue other than a leucine residue; or c) the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1), in which R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein, X1 can be any amino acid residue, and X2 and X3 are amino acid residues other than leucine residues. Preferably, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) Spike (S) protein comprising: a) the amino acid sequence RSXIEDLA (SEQ ID NO:23), where R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein and X can be any amino acid residue; or b) the amino acid sequence RSXIEDAL (SEQ ID NO: 24), where R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein and X can be any amino acid residue; or c) The amino acid sequence RSXIEDAA (SEQ ID NO: 25), where R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein and X can be any amino acid residue.
[0015] The term "genetically encoded amino acid residue" as used in the context of the present invention refers in particular to an amino acid residue (single letter code in brackets) selected from the group consisting of: alanine residue (A), cysteine residue (C), aspartic acid residue (D), glutamic acid residue (E), phenylalanine residue (F), glycine residue (G), histidine residue (H), isoleucine residue (I), lysine residue (K), leucine residue (L), methionine residue (M), asparagine residue (N), proline residue (P), glutamine residue (Q), arginine residue (R), serine residue (S), threonine residue (T), valine residue (V), tryptophan residue (W) and tyrosine residue (Y). The present invention further provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein selected from the group consisting of: (a) a genotype 2a (G2a) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 900 is replaced by an amino acid residue other than leucine; and / or - the leucine residue at amino acid position 901 is replaced by an amino acid residue other than leucine; wherein the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO:2 or SEQ ID NO:39; (b) a genotype 2b (G2b) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 897 is replaced by an amino acid residue other than leucine; and / or - the leucine residue at amino acid position 898 is replaced by an amino acid residue other than leucine; Here, the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein in SEQ ID NO:3.
[0016] Accordingly, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein selected from the group consisting of: (a) a genotype 2a (G2a) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 900 is replaced by an amino acid residue other than leucine and the residue at amino acid position 901 is a leucine residue, or - the residue at amino acid position 900 is a leucine residue and the residue at amino acid position 901 is replaced by an amino acid residue other than a leucine residue, or - the amino acid residues at positions 900 and 901 are replaced by amino acid residues other than leucine residues; wherein the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO:2 or SEQ ID NO:39; (b) a genotype 2b (G2b) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 897 is replaced by an amino acid residue other than leucine and the residue at amino acid position 898 is a leucine residue, or - the residue at amino acid position 897 is a leucine residue and the residue at amino acid position 898 is replaced by an amino acid residue other than a leucine residue, or - the amino acid residues at positions 897 and 898 are replaced by amino acid residues other than leucine residues; Here, the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein in SEQ ID NO:3. As used herein, the phrase "the residues at amino acid positions 900 and 901 are substituted by amino acid residues other than leucine residues" is equivalent to the phrase "the residues at amino acid positions 900 and 901 are each substituted by amino acid residues other than leucine residues" and the phrase "the residues at amino acid positions 897 and 898 are substituted by amino acid residues other than leucine residues" is equivalent to the phrase "the residues at amino acid positions 897 and 898 are each substituted by amino acid residues other than leucine residues".
[0017] It is further understood that the term "genogroup" is equivalent to the term "genotype" often used in the PEDV literature. The terms "genotype 2a (G2a)" and "genotype 2b (G2b)" are well known to those skilled in the art. Phylogenetic studies of the S gene allow PEDV to be genetically classified into two groups: genogroup 1 (G1; classical) and genogroup 2 (G2; field epidemic or pandemic). Each of the genogroups can be further divided into subgroups (1a and 1b; 2a and 2b). G2 contains the worldwide field isolates and is further clustered into the 2a and 2b subgroups, which are responsible for previous localized epidemic outbreaks in Asia and recent pandemic outbreaks in North America and Asia, respectively. The terms "the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO:2 or SEQ ID NO:39" and "the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein of SEQ ID NO:3" should be understood to refer to the amino acid sequence of the full-length wild-type G2a PEDV S protein (SEQ ID NO:2 or SEQ ID NO:39) and the amino acid sequence of the wild-type G2b PEDV S protein (SEQ ID NO:3), respectively. Accordingly, the numbering of the amino acid positions referred to herein is with reference to the wild-type G2a PEDV S protein sequence and the wild-type G2b PEDV S protein sequence (having 1388 or 1386 amino acid residues or 1383 amino acid residues, respectively, and including a methionine residue at (N-terminal) amino acid position 1). Accordingly, the numbering used in the context of the present invention relates to the naturally occurring G2a PEDV S protein and the wild-type G2b PEDV S protein (set forth in SEQ ID NO:2 or SEQ ID NO:39 and SEQ ID NO:3, respectively). In other words, reference to an amino acid or residue at, for example, position 900, means the amino acid corresponding to amino acid 900 in SEQ ID NO:2 or SEQ ID NO:39, respectively. However, this does not mean that the spike proteins of the present invention have an amino acid sequence identical to SEQ ID NO:2 or SEQ ID NO:39, respectively. It is merely stated that the corresponding amino acid in the spike proteins of the present invention encodes the amino acid residue expressly referred to.
[0018] In another specific aspect of the nucleic acid molecule of the invention, the amino acid residue other than leucine is selected from the group consisting of alanine, glycine, isoleucine, methionine and valine residues. In another specific aspect of the nucleic acid molecule of the invention, the amino acid residue other than leucine residue is selected from the group consisting of alanine residues or glycine residues. Thus, the invention particularly provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) Spike (S) protein comprising: a) the amino acid sequence RSXIEDLA (SEQ ID NO:23), or b) the amino acid sequence RSXIEDAL (SEQ ID NO:24), or c) the amino acid sequence RSXIEDAA (SEQ ID NO:25), or d) the amino acid sequence RSXIEDLG (SEQ ID NO:31), or e) the amino acid sequence RSXIEDGL (SEQ ID NO:32), or f) the amino acid sequence RSXIEDGG (SEQ ID NO:33), or g) the amino acid sequence RSXIEDGA (SEQ ID NO:34), or h) the amino acid sequence RSXIEDAG (SEQ ID NO:35); wherein R is the conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, and X can be any amino acid residue.
[0019] In another specific aspect of the nucleic acid molecule of the invention, said amino acid residue other than leucine residue is an alanine residue. In another specific aspect of the nucleic acid molecule of the invention, the numbering of the amino acid positions refers to the amino acid sequence RSXIEDLLF (SEQ ID NO: 4) of the wild-type G PEDV S protein, where R is the conserved arginine residue of the S1 / S2 cleavage site, and LL is amino acid positions 900 and 901 in genotype 2a (G2a) PEDV S, or LL is amino acid positions 897 and 898 in genotype 2b (G2b) PEDV S. In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein comprises the amino acid sequence RSXIEDAAF (SEQ ID NO:5), where R is a conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, and AA is amino acid positions 900 and 901 in genotype 2a (G2a) PEDV S, or AA is amino acid positions 897 and 898 in genotype 2b (G2b) PEDV S.
[0020] In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein comprises the amino acid sequence X1X2X3FX4KX5X6X7X8 (SEQ ID NO: 6), wherein X8 is the C-terminal amino acid residue of the PEDV S protein or is the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein; X2 to X5, X7 and X8 can be any amino acid residue; and (i) X1 is an amino acid residue other than a tyrosine residue and X6 is a histidine residue; or (ii) X1 is a tyrosine residue and X6 is an amino acid residue other than a histidine residue; or (iii) X1 is an amino acid residue other than a tyrosine residue, and X6 is an amino acid residue other than a histidine residue. Preferably, in the context of the present invention, X8 is the C-terminal amino acid residue of said PEDV S protein when said PEDV S protein is a genotype 2b (G2b) PEDV S protein, or X8 is the amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein when said PEDV S protein is a genotype 2a (G2a) PEDV S protein. The term "amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein" is specifically understood to be equivalent to "amino acid residue at amino acid position n-2, where n is the amino acid position of the C-terminal amino acid residue of said PEDV S protein". Thus, for example, if a PEDV protein (e.g., a genotype 2a (G2a) PEDV S protein) has an amino acid sequence that is 1388 amino acids in length, then the amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein is the amino acid residue at amino acid position 1386 of said PEDV protein or of a genotype 2a (G2a) PEDV S protein, respectively. Furthermore, as described herein, the phrase "X2 through X5, X7 and X8 can be any amino acid residue" is specifically understood to be equivalent to "each of X2 through X5, X7 and X8 can be any amino acid residue." Furthermore, the phrase "X2, X3, X4, X5, X6, and X7 can be any amino acid residue" is equivalent to "X2, X3, X4, X5, X6, and X7 can each be any amino acid residue", "X1, X2, X3, X4, X6, and X7 can each be any amino acid residue" is equivalent to "X1, X2, X3, X4, X6, and X7 can each be any amino acid residue", and "X2, X3, X4, X5, X7, and X8 can be any amino acid residue" is equivalent to "X2, X3, X4, X5, X7, and X8 can each be any amino acid residue". Advantageously, said modification in the retention signal of the spike protein to X1X2X3FX4KX5X6X7X8 (SEQ ID NO: 6) results in localization of the spike protein in the plasma membrane. Furthermore, these modifications improve the production process of PEDV vaccines, especially with regard to the stability of the recombinant vector, and may additionally allow the propagation of the recombinant vector at higher titers in production cell lines due to the disruption of the biological activity of the PEDV spike protein by the described mutations.
[0021] Further, the present invention provides a nucleic acid molecule encoding a Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein comprising the amino acid sequence X1X2X3FX4KX5X6X7X8 (SEQ ID NO: 6), X8 is the C-terminal amino acid residue of the PEDV S protein or is the amino acid residue at position −2 relative to the C-terminal amino acid position of the PEDV S protein; X2 to X5, X7 and X8 can be any amino acid residue; (i) X1 is an amino acid residue other than a tyrosine residue and X6 is a histidine residue; or (ii) X1 is a tyrosine residue and X6 is an amino acid residue other than a histidine residue; or (iii) X1 is an amino acid residue other than a tyrosine residue, and X6 is an amino acid residue other than a histidine residue; Preferably, X7 is - the C-terminal amino acid residue of the PEDV S protein when the PEDV S protein is a genotype 2b (G2b) PEDV S protein; or - when said PEDV S protein is a genotype 2a (G2a) PEDV S protein, the amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein.
[0022] In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein further comprises: a) an amino acid sequence X1X2X3FX4KX5HX6X7 (SEQ ID NO: 26), in which X7 is the C-terminal amino acid residue of the PEDV S protein or the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein, X1 is an amino acid residue other than a tyrosine residue, and X2, X3, X4, X5, X6, and X7 can be any amino acid residue; and X7 is preferably - the C-terminal amino acid residue of the PEDV S protein when the PEDV S protein is a genotype 2b (G2b) PEDV S protein; or - the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein when the PEDV S protein is a genotype 2a (G2a) PEDV S protein; or b) an amino acid sequence YX1X2FX3KX4X5HX6X7 (SEQ ID NO: 27), in which X7 is the C-terminal amino acid residue of the PEDV S protein or the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein, X5 is an amino acid residue other than a histidine residue, and X1, X2, X3, X4, X6, and X7 can be any amino acid residue; and X7 is preferably - the C-terminal amino acid residue of the PEDV S protein when the PEDV S protein is a genotype 2b (G2b) PEDV S protein; or - the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein when the PEDV S protein is a genotype 2a (G2a) PEDV S protein; or c) the amino acid sequence X1X2X3FX4KX5X6X7X8 (SEQ ID NO: 6), where X8 is the C-terminal amino acid residue of the PEDV S protein or the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein, X1 is an amino acid residue other than a tyrosine residue, X6 is an amino acid residue other than a histidine residue, and X2, X3, X4, X5, X7, and X8 can be any amino acid residue; and X8 is preferably - the C-terminal amino acid residue of the PEDV S protein when the PEDV S protein is a genotype 2b (G2b) PEDV S protein; or - when said PEDV S protein is a genotype 2a (G2a) PEDV S protein, the amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein.
[0023] In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein further comprises: a) Amino acid sequence AXXFXKXHXX- COOH (SEQ ID NO:28), or b) Amino acid sequence YXXFXKXRXX- COOH (SEQ ID NO:29), or c) the amino acid sequence AXXFXKXRXX- COOH (SEQ ID NO: 30), Here, X- COOH is the C-terminal amino acid residue of the PEDV S protein or is the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein, and X can be any amino acid residue; And X- COOH is preferably - the C-terminal amino acid residue of the PEDV S protein when the PEDV S protein is a genotype 2b (G2b) PEDV S protein; or - when said PEDV S protein is a genotype 2a (G2a) PEDV S protein, the amino acid residue at position -2 relative to the C-terminal amino acid position of said PEDV S protein. In another particular aspect of the nucleic acid molecule of the invention, (a) the G2a PEDV S protein, the tyrosine residue at amino acid position 1377 is replaced by an amino acid residue other than tyrosine, and / or the histidine residue at amino acid position 1384 is replaced by an amino acid residue other than a histidine residue, or (b) the G2b PEDV S protein, the tyrosine residue at amino acid position 1374 is replaced by an amino acid residue other than tyrosine, and / or the histidine residue at amino acid position 1381 is replaced by an amino acid residue other than histidine; As defined above, the numbering used in the context of the present invention relates to the sequences of the naturally occurring G2a PEDV S protein and the wild-type G2b PEDV S protein (shown in SEQ ID NO:2 or SEQ ID NO:39 and SEQ ID NO:3, respectively).
[0024] In another particular aspect of the nucleic acid molecule of the invention, (a) the G2a PEDV S protein, the tyrosine residue at amino acid position 1377 is replaced by an amino acid residue other than a tyrosine residue and the residue at amino acid position 1384 is a histidine residue, or the residue at amino acid position 1377 is a tyrosine residue and the histidine residue at amino acid position 1384 is replaced by an amino acid residue other than a histidine residue, or the tyrosine residue at amino acid position 1377 is replaced by an amino acid residue other than a tyrosine residue and the histidine residue at amino acid position 1384 is replaced by an amino acid residue other than a histidine residue, or (b) the G2b PEDV S protein, the tyrosine residue at amino acid position 1374 is replaced by an amino acid residue other than a tyrosine residue and the residue at amino acid position 1381 is a histidine residue, or the residue at amino acid position 1374 is a tyrosine residue and the histidine residue at amino acid position 1381 is replaced by an amino acid residue other than a histidine residue, or the tyrosine residue at amino acid position 1374 is replaced by an amino acid residue other than a tyrosine residue, and the histidine residue at amino acid position 1381 is replaced by an amino acid residue other than a histidine residue. In another particular aspect of the nucleic acid molecule of the invention, the amino acid residues other than tyrosine residues are selected from the group consisting of alanine, glycine, leucine, isoleucine, methionine and valine residues; and / or The amino acid residues other than the histidine residues are arginine residues. In another particular aspect of the nucleic acid molecule of the invention, - the amino acid residues other than tyrosine residues are alanine residues, and / or The amino acid residues other than the histidine residues are arginine residues.
[0025] In another specific aspect of the nucleic acid molecule of the invention, the numbering of the amino acid positions refers to the amino acid sequence YXXFXKXH (SEQ ID NO:7) of the wild-type G PEDV S protein, where Y and H are amino acid positions 1377 and 1384 in the genotype 2a (G2a) PEDV S protein, or Y and H are amino acid positions 1374 and 1381 in the genotype 2b (G2b) PEDV S protein. In another specific aspect of the nucleic acid molecule of the invention, the nucleic acid molecule comprises a sequence encoding the amino acid sequence AXXFXKXR (SEQ ID NO:8), wherein A and R are amino acid positions 1377 and 1384 in the genotype 2a (G2a) PEDV S protein, or wherein A and R are amino acid positions 1374 and 1381 in the genotype 2b (G2b) PEDV S protein. In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein comprises i) (a) comprising or consisting of an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 15, 16, 17, 18, 19, 20, 40; or (b) comprising or consisting of an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 9, 10, 11, 12, 13, and 14; and / or ii) (a) is encoded by a nucleotide sequence encoding an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 15, 16, 17, 18, 19, 20, and 40; or (b) encoded by a nucleotide sequence encoding an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 9, 10, 11, 12, 13, and 14.
[0026] The term "identity" or "sequence identity" is known in the art and refers to the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, i.e., a reference sequence and a given sequence to be compared to the reference sequence. Sequence identity is determined by comparing a given sequence to a reference sequence after optimally aligning the sequences to achieve the highest degree of sequence similarity (as determined by the match between a stretch of such sequences). Upon such alignment, sequence identity is ascertained on a position-by-position basis. For example, if the nucleotide or amino acid residue at a particular position is identical, then the sequences are "identical" at that particular position. The total number of such position identities is divided by the total number of nucleotides or residues in the reference sequence to obtain the % sequence identity. Sequence identity can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, AN, ed., Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), the teachings of which are incorporated herein by reference.Preferred methods of determining sequence identity are designed to produce the largest match between the sequences examined. Methods for determining sequence identity are codified in publicly available computer programs that determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research, 12(1):387(1984)), BLASTP, BLASTN and FASTA (Altschul, SF et al., J. Molec. Biol., 215:403-410(1990). The BLASTX program is available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, MD 20894; Altschul, SF et al., J. Molec. Biol., 215:403-410 (1990), the teachings of which are incorporated herein by reference. These programs optimally align sequences using a predefined gap weight to achieve a high level of sequence identity between a given sequence and a reference sequence. By way of illustration, a polynucleotide having a nucleotide sequence with, for example, at least 85%, preferably 90%, more preferably 95% "sequence identity" to a reference nucleotide sequence is intended to mean that the nucleotide sequence of the given polynucleotide is identical to the reference sequence except that it has up to 15, preferably up to 10, more preferably up to 5 point mutations for each 100 nucleotides of the reference nucleotide sequence. In other words, in a polynucleotide having a nucleotide sequence with at least 85%, preferably 90%, more preferably 95% identity to a reference sequence, up to 15%, preferably 10%, more preferably 5% of the nucleotides of the reference sequence may be deleted or replaced with another nucleotide, or up to 15%, preferably 10%, more preferably 5% of the total nucleotides of the reference sequence may be inserted into the reference sequence.These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between these terminal positions, or may be scattered among the nucleotides of the reference sequence individually or in one or more contiguous groups within the reference sequence. Similarly, by a polypeptide having an amino acid sequence with, for example, at least 85%, preferably 90%, more preferably 95% sequence identity to a reference amino acid sequence, it is intended that the amino acid sequence of the polypeptide is identical to the reference sequence, except that the polypeptide sequence may contain up to 15, preferably up to 10, more preferably up to 5 amino acid mutations for each 100 amino acids of the reference amino acid sequence. In other words, to obtain a polypeptide sequence with at least 85%, preferably 90%, more preferably 95% sequence identity to the reference amino acid sequence, up to 15%, preferably up to 10%, more preferably up to 5% of the amino acid residues of the reference sequence may be deleted or replaced with another amino acid, or up to 15%, preferably up to 10%, more preferably up to 5% of the total number of amino acid residues of the reference sequence may be inserted into the reference sequence. These variations in the reference sequence may occur at or anywhere between the amino or carboxy terminal positions of the reference amino acid sequence, or may be interspersed among the residues of the reference sequence either individually or in one or more contiguous groups within the reference sequence. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included in matches when determining sequence identity.
[0027] The terms "identity", "sequence identity" and "percent identity" are used interchangeably herein. For purposes of the present invention, to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison (e.g., gaps can be introduced into a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid or nucleotide residues at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid or nucleotide residue as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions (i.e., overlapping positions) x 100). Preferably, the two sequences are the same length. Sequence comparisons can be performed over the entire length of the two sequences being compared, or over fragments of the two sequences. Typically, comparisons will be performed over the full length of the two sequences. However, sequence identity can be performed over a region of, for example, 20, 50, 100 or more contiguous amino acid residues.
[0028] Those skilled in the art will be aware of the fact that various computer programs are available for determining the homology between two sequences. For example, the comparison of sequences and the determination of the percent identity between two sequences can be achieved using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid or nucleic acid sequences is determined using the algorithm of Needleman and Wunsch (Needleman and Wunsch, J. Mol. Biol. (48):444-453(1970)), which is incorporated in the GAP program of the Accelrys GCG software package (available at http: / / www.accelrys.com / products / gcg / ), using either Blosum 62 matrix or PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6 or 4 and length weights of 1, 2, 3, 4, 5 or 6. One of skill in the art will recognize that all these different parameters will produce slightly different results, but the overall percentage identity of the two sequences will not change significantly when using different algorithms. The protein or nucleic acid sequences of the invention can also be used as a "query sequence" to perform a search of public databases, e.g., to identify other family members or related sequences. Such searches can be performed using the BLASTN and BLASTP programs (version 2.0) of Altschul et al. (1990) J. Mol. Biol. 215:403-10. BLAST protein searches can be performed using the BLASTP program (score=50, wordlength=3) to obtain amino acid sequences homologous to the protein molecules of the invention. To achieve gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTP and BLASTN) can be used. Please refer to the National Center for Biotechnology Information homepage (http: / / www.ncbi.nlm.nih.gov / ).
[0029] As used herein, the term "identical to the sequence of SEQ ID NO:Y" is equivalent to the terms "identical to the sequence of SEQ ID NO:Y over the length of SEQ ID NO:Y" or "identical to the sequence of SEQ ID NO:Y over the entire length of SEQ ID NO:Y", respectively. In this context, "Y" is any integer selected from 1 to 40, and "SEQ ID NO:Y" represents any number of SEQ ID NOs referred to herein. In another specific aspect of the nucleic acid molecule of the invention, the PEDV S protein comprises (a) comprising any one of the amino acid sequences of SEQ ID NOs: 15, 16, 17, 18, 19, 20, and 40; or (b) Contains any one of the amino acid sequences of SEQ ID NO:9, 10, 11, 12, 13, and 14. In an illustrative, non-limiting example, a nucleic acid molecule of the invention comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38. Additionally, the present invention provides PEDV(S) proteins encoded by the nucleic acid molecules described herein. In another particular aspect of the nucleic acid molecule or PEDV S protein of the invention, the nucleic acid molecule encoding the PEDV S protein or the PEDV S protein is recombinant.
[0030] The term "recombinant" as used herein refers to a polynucleotide (including a DNA molecule, an RNA molecule, a cDNA molecule, or derivatives) or a polypeptide that has any modification that does not occur in nature relative to the corresponding polynucleotide or polypeptide. For example, a polynucleotide or polypeptide is considered "recombinant" if it contains an insertion, deletion, inversion, rearrangement, or point mutation that is artificially introduced (e.g., by human intervention). Thus, the polynucleotide or polypeptide is not associated with all or part of the sequence (polynucleotide or polypeptide) with which it is naturally associated. The term "recombinant" as used in reference to a virus refers to a virus that is produced by the artificial manipulation of the genome of that virus. The term "recombinant virus" encompasses viruses that have been genetically modified. Preferably, the proteins of the invention are non-naturally occurring proteins. Preferably, the protein is an isolated protein. The present invention further provides polynucleotides comprising the nucleic acid molecules described herein. The production of the nucleic acid molecules and polynucleotides described herein is within the skill of the art and can be carried out according to recombinant techniques, as described, inter alia, in Sam brook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Amusable, et al., 2003, Current Protocols In Molecular Biology, Greene Publishing Associates & Wiley Interscience, NY; Innis et al. (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1994, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.
[0031] The present invention further provides a vector comprising a nucleic acid molecule described herein or a polynucleotide described herein. The term "vector" as known in the art refers to a polynucleotide construct, typically a plasmid or bacterial artificial chromosome, used to transfer genetic material to a host cell. A vector can be, for example, a bacterium, a virus, a phage, a bacterial artificial chromosome, a cosmid, or a plasmid. A vector as used herein can comprise or contain either DNA or RNA. In some embodiments, a vector comprises DNA. In some embodiments, a vector is an infectious virus. Such viral vectors contain a viral genome that has been engineered to carry a foreign gene that is non-functional for replication of the viral vector in cell culture or in a host animal. According to specific features of the present disclosure, vectors can be used for a variety of functions, such as simply transferring genetic material, for transfection of a host cell or organism, for use as a vaccine (e.g., a DNA vaccine), or for gene expression purposes. Gene expression is a term that describes the biosynthesis of a protein in a cell that is directed by a specific polynucleotide sequence, called a gene. In a particular aspect, a vector can be an "expression vector," which is a vector that, when present in the appropriate environment, is capable of directing the expression of a protein encoded by one or more genes carried by the vector.
[0032] Vectors and methods of use for making and / or expressing vectors (or recombinants) may be by methods or similar methods disclosed in US Pat. Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 4,722,848, 5,942,235, 5,364,773, 5,762,938, 5,770,212, 5,942,235, 382,425, PCT publications WO 94 / 16716, WO 96 / 39491, WO 95 / 30018; Paoletti, “Applications of pox virus vectors to vaccination: An update”, PNAS USA 93: 11349-11353, October 2002. 1996; Moss, “Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety”, PNAS USA 93: 11341-11348, October 1996; Smith et al., US Pat. No. 4,745,051 (recombinant baculovirus); Richardson, CD (Editor), Methods in Molecular Biology 39, “Baculovirus Expression Protocols”(1995 Humana Press Inc.);Smith et al., “Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector”, Molecular and Cellular Biology, December, 1983, Vol. 3, No. 12, p. 2156-2165;Pennock et al.,“Strong and Regulated Expression of Escherichia coli B-Galactosidase in Infect Cells with a Baculovirus vector”, Molecular and Cellular Biology March 1984, Vol. 4, No. 3, p. 406;EPA0 370 573;U.S. Application No. 920,197 (filed October 16, 1986);EP Patent Publication No. 265785;US Pat. No. 4,769,331 (recombinant herpes viruses);Roizman,“The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors”,PNAS USA 93:11307-11312, October 1996;Andreansky et al.,“The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors”,PNAS USA 93: 11313-11318, October 1996;Robertson et al., “Epstein-Barr virus vectors for gene delivery to B lymphocytes”, PNAS USA 93: 11334-11340, October 1996;Frolov et al., “Alphavirus-based expression vectors: Strategies and applications,” PNAS USA 93: 11371-11377, October 1996;Kitson et al., J. Virol. 65, 3068-3075, 1991; US Pat. Nos. 5,591,439, 5,552,143; WO 98 / 00166; Granted US Application Ser. Nos.08 / 675,556 and 08 / 675,566 (both filed July 3, 1996 (recombinant adenovirus); Grunhaus et al., 1992, “Adenovirus as cloning vectors”, Seminars in Virology (Vol. 3) p. 237-52, 1993; Ballay et al. EMBO Journal, vol. 4, p. 3861-65, Graham, Tibtech 8, 85-87, April, 1990;Prevec et al., J. Gen Virol. 70, 42434;PCT WO 91 / 11525;Felgner et al. (1994), J. Biol. 1745-49, 1993; McClements et al., "Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease", PNAS USA 93: 11414-11420, October 1996; and US Pat. Nos. 5,591,639, 5,589,466, and 5,580,859, among others, WO 90 / 11092, WO93 / 19183, WO94 / 21797, WO95 / 11307, WO95 / 20660; Tang et al., Nature, and Furth et al., Analytical Biochemistry, relating to DNA expression vectors. See also, WO 98 / 33510; Ju et al., Diabetologia, 41: 736-739, 1998 (lentiviral expression systems); Sanford et al., US Pat. No. 4,945,050; Fischbach et al. (Intracel); WO 90 / 01543; Robinson et al., Seminars in Immunology vol. 9, pp. 271-283 (1997), (DNA vector systems); Szoka et al., US patent No. 4,394,448 (methods for inserting DNA into living cells); McCormick et al., US Pat. No. 5,677,178 (use of cytopathic viruses); and US Pat. No. 5,928,913 (vectors for gene delivery); and other documents cited herein.
[0033] Preferably, the vector is a viral vector. The term "viral vector" refers to a genetically modified virus that has been engineered by recombinant DNA techniques such that entry of the vector into a host cell results in a specific biological activity, such as expression of a transgene carried by the vector. In a particular aspect, the transgene is an antigen. A viral vector may or may not be replication-competent in a target cell, tissue or organism. As used herein, the term "viral vector" is equivalent to "virus vector." The generation of viral vectors is accomplished using any suitable genetic engineering technique known in the art, including but not limited to standard techniques for restriction endonuclease digestion, ligation, transformation, plasmid purification, DNA sequencing, transfection of cell culture, as described, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, 1989; or K. Maramorosch and H. Koprowski (Methods in Virology Volume VIII, Academic Press Inc. London, UK, 2014). Viral vectors can incorporate sequences from the genome of any known organism. The sequences can be incorporated in their natural form or can be modified in any manner to obtain the desired activity. For example, the sequences can include insertions, deletions, or substitutions. In a particular aspect of the invention, the vector is CDV (canine distemper virus), EHV (equine herpes virus) or ORF virus (parapoxvirus), PRV (pseudorabies virus), CAV (canine adenovirus), PCMV (porcine cytomegalovirus), or BoHV-4 (bovine herpesvirus-4). In a particular aspect of the vector of the invention, the vector is CDV or EHV.
[0034] Additionally, the present invention provides immunogenic compositions comprising a nucleic acid molecule encoding a PEDV S protein described herein and / or a PEDV S protein described herein and / or a vector described herein. The term "immunogenic composition" refers to a composition comprising at least one antigen that elicits an immunological response in a host to which the immunogenic composition is administered. Such an immunological response can be a cellular and / or antibody-mediated immune response to the immunogenic composition of the invention. Preferably, the immunogenic composition elicits an immune response, more preferably, confers protective immunity against one or more of the clinical signs of PEDV infection. The host is also described as a "subject." Any host or subject described or referred to herein is a piglet, a pig or a sow. Typically, an "immunological response" includes, but is not limited to, one or more of the following effects: production or activation of antibodies, B cells, helper T cells, suppressor T cells, and / or cytotoxic T cells, and / or gamma-delta T cells specifically directed against the antigen or antigens contained in the immunogenic composition of the invention. Preferably, the host will mount a protective immune response or a therapeutic response. A "protective immunological response" or "protective immunity" will be manifested by either a reduction or absence of clinical signs normally exhibited by an infected host, a more rapid recovery time and / or a shortened duration of infectivity, or a lower titer of pathogen in the tissues, fluids or secretions of the infected host. If the host mounts a protective immunological response which enhances resistance to new infection and / or reduces the clinical severity of the disease, the immunogenic composition is described as a "vaccine."
[0035] In another specific aspect of the immunogenic composition of the invention, the immunogenic composition further comprises a pharma- ceutically acceptable carrier. The term "pharmaceutical acceptable carrier" includes any and all solvents, dispersion media, coatings, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, absorption delaying agents, adjuvants, immunostimulants, and combinations of the above. "Diluents" may include water, saline, dextrose, ethanol, glycerol, etc. Isotonic agents may include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin and alkali salts of ethylenediaminetetraacetic acid, among others. In one aspect of the invention, the pharma- ceutically acceptable carrier is phosphate buffered saline. Preferably, the immunogenic composition further comprises a sucrose gelatin stabilizer. In one aspect of the invention, the pharma- ceutically acceptable carrier is chitosan. Chitosan is a natural deacetylated polysaccharide derived from chitin in crustaceans (e.g. shrimp, crabs), insects, and other invertebrates. Recently, Rauw et al. (Rauw et al. 2009, Vet Immunol Immunop 134:249-258) showed that chitosan enhances the cellular immune response of live Newcastle disease vaccine and promotes its protective effect. Furthermore, Wamg et al. (Wang et al., Arch Virol (2012) 157:1451-1461) presented results demonstrating the potential of chitosan as an adjuvant for use in live attenuated influenza vaccines. Preferably, the immunogenic composition can further include one or more other immunomodulatory agents (e.g., interleukins, interferons, or other cytokines). The amounts and concentrations of adjuvants and additives useful in the context of the present invention can be readily determined by one of skill in the art.
[0036] In some aspects, the immunogenic compositions of the invention include an adjuvant. As used herein, "adjuvants" may include aluminum hydroxide and aluminum phosphate, saponins such as Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL), water-in-oil emulsions, oil-in-water emulsions, water-in-oil-in-water emulsions. The emulsions may be based, among others, on plasma liquid paraffin oil (European Pharmacopoeia type); isoprenoid oils, such as squalane or squalene; oils resulting from the oligomerization of alkenes, particularly isobutene or decene; esters of acids or alcohols containing linear alkyl groups, more particularly vegetable oils, ethyl oleate, propylene glycol di-(caprylate / caprate), glyceryl tri-(caprylate / caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, particularly isostearate esters. The oil is used together with an emulsifier to form an emulsion.The emulsifier is preferably a non-ionic surfactant, in particular esters of sorbitan, esters of mannides (e.g. anhydromannitol oleate), esters of glycols, esters of polyglycerols, esters of propylene glycol, and esters of oleic acid, isostearic acid, ricinoleic acid or hydroxystearic acid (optionally ethoxylated), as well as polyoxypropylene-polyoxyethylene copolymer blocks, in particular Pluronic products, in particular L121.See Hunter et al., The Theory and Practical Application of Adjuvants (Ed.Stewart-Tull, DES), JohnWiley and Sons, NY, pp51-94, 1995; and Todd et al., Vaccine 15:564-570, 1997.Exemplary adjuvants are the SPT emulsion described on page 147 in the book "Vaccine Design, The Subunit and Adjuvant Approach", edited by M. Powell and M. Newman, Plenum Press, 1995) and emulsion MF59 described on page 183 of the same book.
[0037] Further examples of adjuvants are compounds selected from polymers of acrylic or methacrylic acid and copolymers of maleic anhydride and alkenyl derivatives. Advantageous adjuvant compounds are polymers of acrylic or methacrylic acid, which are crosslinked, in particular with polyalkenyl ethers of sugars or polyalcohols. These compounds are known under the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). The skilled artisan may also refer to US Pat. No. 2,909,462 (which describes acrylic acid polymers crosslinked with polyhydroxylated compounds, having at least three hydroxyl groups (preferably not more than eight), at least three hydroxyl hydrogen atoms being replaced by unsaturated fatty acid radicals having at least two carbon atoms). Preferred radicals are those containing from 2 to 4 carbon atoms, such as vinyl, allyl and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents, such as methyl. Particularly suitable are products sold under the name Carbopol (BF Goodrich, Ohio, USA). They are crosslinked with allyl sucrose or allyl pentaerythritol. Among them, Carbopol 974P, 934P and 971P can be mentioned. The use of Carbopol 971 is most preferred. Among the copolymers of maleic anhydride and alkenyl derivatives is the copolymer EMA (Monsanto), which is a copolymer of maleic anhydride and ethylene. The dissolution of these copolymers in water gives an acid solution, which will be neutralized, preferably to physiological pH, to give an adjuvant solution into which the immunogenic, immunological or vaccine composition itself will be incorporated.
[0038] Further suitable adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), block copolymers (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), monophosphoryl lipid A, avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or other form), cholera toxin, IMS 131 or muramyl dipeptide, or naturally occurring or recombinant cytokines or analogs thereof, or endogenous cytokine release stimulators, among many others. It is expected that the adjuvant may be added in an amount of about 100 μg to about 10 mg / dose, preferably in an amount of about 100 μg to about 10 mg / dose, more preferably in an amount of about 500 μg to about 5 mg / dose, even more preferably in an amount of about 750 μg to about 2.5 mg / dose, and most preferably in an amount of about 1 mg / dose. Alternatively, the adjuvant may be present in a concentration of about 0.01 to 50%, preferably in a concentration of about 2% to 30%, more preferably in a concentration of about 5% to 25%, even more preferably in a concentration of about 7% to 22%, and most preferably in a concentration of 10% to 20% by volume of the final product.
[0039] In another specific aspect of the immunogenic composition of the invention, the immunogenic composition is a vaccine. The term "vaccine" has already been described elsewhere herein. However, an immunogenic composition is described as a "vaccine" if the host exhibits a protective immunological response that enhances resistance to new infection and / or reduces the severity of clinical signs of disease. The present invention further provides a cell comprising a nucleic acid molecule described herein, a polynucleotide described herein, or a vector described herein. The present invention further provides a nucleic acid molecule encoding a PEDV S protein described herein and / or a method for producing a PEDV S protein described herein, the method comprising transfecting a cell with a vector described herein. Furthermore, the present invention provides a method for preparing an immunogenic composition for treating and / or preventing PEDV infection in a subject, comprising the steps of: a.) infecting cells with a vector described herein; b.) obtaining said vector; c.) Adding a pharma-ceutically acceptable carrier.
[0040] The term "obtaining" includes collecting, isolating, purifying, and / or preparing (eg, polishing, inactivating, and / or blending) the antigen. The term "harvesting" refers to collecting or recovering the vector from a transfected cell or cell line. Any conventional method known in the art (e.g., any separation method) can be used to recover the vector. Methods known in the art include centrifugation or filtration (e.g., using a semi-permeable membrane with a defined pore size). The term "isolation" includes a process for isolating said vector. Methods for isolating said vector from infected cells or cell lines are known to those skilled in the art. These methods include physical and / or chemical methods, including, but not limited to, repeated freeze-thawing, sonication, etc. Methods for "purifying" said vector from the isolate are known to the skilled artisan, for example by methods described in the literature (Protein purification methods - a practical approach (ELV Harris and S. Angel, eds., IRL Press at Oxford University Press)). These methods include, but are not limited to, separation by centrifugation and / or filtration, precipitation, size exclusion (gel filtration) chromatography, affinity chromatography, metal chelate chromatography, ion exchange chromatography, covalent binding chromatography, hydrophobic interaction chromatography, etc. The vector is obtained in purified pure form or is obtained free or substantially free of other cellular material or culture medium. After said isolation and / or purification, the antigen exhibits a purity of at least 80%, preferably 80%-90%, more preferably 90%-97%, most preferably 97% up to completely pure without any contaminants. According to a further feature, "obtaining" as used herein may also include further polishing steps (eg, addition of buffers, inactivation, neutralization steps, etc.) as part of the final formulation process.
[0041] Preferably, the cells are derived from a eukaryotic cell line. In a particular aspect of the method of the invention, the cell is a Vero cell, an ST cell or a BHK-21, Ma104, MDBK, RK13, MDCK or PK15 cell. All cells mentioned are known to those skilled in the art and publicly available. Vero cells are, for example, deposited at the American Type Culture Collection under accession number ATCC CCL-81. ST cells are, for example, deposited at the American Type Culture Collection under accession number CRL-1746. BHK-21 cells are, for example, deposited at the American Type Culture Collection under accession number ATCC CCL-10. MDCK cells are, for example, deposited at the American Type Culture Collection under accession number ATCC CCL-34 or ATCC CRL-2285. In another specific aspect of the immunogenic compositions or methods of the invention, the pharma- ceutically acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, absorption delaying agents, adjuvants, immunostimulants, and combinations thereof.
[0042] Furthermore, the present invention provides a method of immunizing a subject, said method comprising the step of administering to such a subject an immunogenic composition described herein. Advantageously, the immunogenic compositions of the present invention have been proven safe and effective. The term "immunizing" refers to active immunization by administering an immunogenic composition to the subject to be immunized, thereby eliciting an immunological response against the antigen contained in such immunogenic composition. Preferably, immunity results in a reduction in the occurrence of a particular PEDV infection in a herd, or a reduction in the severity of clinical signs caused by or associated with a particular PEDV infection. Moreover, immunization of a subject in need with the immunogenic composition provided herein results in the prevention of infection with PEDV in the subject. More preferably, the immunization results in an effective and long-lasting immunological response against PEDV infection. It will be understood that the period will last for more than one month, preferably more than two months, preferably more than three months, more preferably more than four months, more preferably more than five months, more preferably more than six months. It should be understood that immunity is not effective in all subjects that are immunized. However, the term requires that a significant portion of the subjects in the herd are effectively immunized.
[0043] Preferably, in this context, it is assumed that the subjects of the herd would normally (i.e. without immunization) develop clinical signs normally caused by or associated with PEDV infection. Whether the subjects of the herd are effectively immunized or not can be determined without further ado by the skilled artisan. Preferably, the immunization will be effective if the clinical signs are reduced in incidence or severity by at least 10%, more preferably at least 20%, even more preferably at least 30%, even more preferably at least 40%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably at least 100% in at least 33%, at least 50%, at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably at least 100% in at least 33%, at least 50%, at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably at least 100% in at least 30%, at least 40%, even more preferably at least 50%, even more preferably ...
[0044] Furthermore, the present invention provides a method for treating and / or preventing clinical signs caused by PEDV infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition described herein. Advantageously, the immunogenic compositions of the present invention have been demonstrated to reduce the clinical signs caused by PEDV infection. The term "treating and / or preventing" refers to a reduction in the incidence of a specific PEDV infection in a herd or a reduction in the severity of clinical signs caused by or associated with a PEDV infection. Thus, the term "treating and / or preventing" also refers to a reduction in the number of subjects infected with a specific PEDV in a herd (= a reduction in the incidence of a specific PEDV infection), or a reduction in viral shedding after a specific PEDV infection, or prevention or reduction of diarrhea after a specific PEDV infection, in a group of subjects given an effective amount of an immunogenic composition provided herein, compared to a group of subjects not given such immunogenic composition. "Treatment and / or prevention" generally entails administering an effective amount of the immunogenic composition of the invention to a subject or a group of subjects in need thereof or who may benefit from such treatment / prevention. The term "treat" refers to administering an effective amount of the immunogenic composition once a subject or several subjects of a group have been infected with such PEDV and when such subjects show some clinical signs caused by or associated with such PEDV infection. The term "prevent" refers to administering to such subjects prior to any infection of the subject with PEDV or when none of such subjects or subjects in a group of subjects shows at least any clinical signs caused by or associated with such PEDV infection. "Prophylaxis" and "preventing" are used interchangeably in this application.
[0045] The term "effective amount" as used herein refers to an amount (including but not limited to the amount of antigen) that induces or is capable of eliciting an immune response in a subject. Such an effective amount can reduce the incidence of a particular PEDV infection in a herd or reduce the severity of clinical signs of a particular PEDV infection. Preferably, clinical signs are reduced in incidence or severity by at least 10%, more preferably at least 20%, even more preferably at least 30%, even more preferably at least 40%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100%, compared to subjects who are not treated or who are treated with an immunogenic composition available prior to the present invention but who are subsequently infected with a particular PEDV. The term "clinical signs" as used herein refers to a subject's infection signs resulting from PEDV. Examples of such clinical signs include, but are not limited to, viral load, diarrhea, viral shedding, elevated body temperature, mortality, gross lesions in the intestine, depression, weight loss, reduced growth rate, and reduced appetite. However, clinical signs also include, but are not limited to, clinical signs that can be directly observed in live animals. Examples of clinical signs that can be directly observed in live animals can include, but are not limited to, weight loss, reduced growth rate, reduced appetite, diarrhea, watery diarrhea, vomiting, lameness, lethargy, wasting, and stunted growth. Preferably, clinical signs that occur at a reduced incidence or severity in treated subjects compared to subjects who are untreated or who have been treated with an immunogenic composition available prior to the present invention but who are subsequently infected with a particular PEDV refer to reduced weight loss, lower viral load, reduced diarrhea, reduced viral shedding, reduced rectal temperature, reduced mortality, reduced gross lesions in the intestine, or a combination thereof. The term "in need" or "necessary" as used herein means that administration / treatment is accompanied by an aid or improvement in the health condition or clinical signs of the subject given the immunogenic composition of the invention, or any other positive medical effect on the health condition.
[0046] Additionally, the present invention provides a method for reducing diarrhea in a subject compared to a non-immune control group of subjects of the same species, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition described herein. Additionally, the present invention provides a method for reducing mortality in a subject compared to a non-immune control group of subjects of the same species, said method comprising administering to the subject a therapeutically effective amount of an immunogenic composition described herein. The term "reducing mortality" means a reduction in mortality rate by at least 10%, more preferably at least 20%, even more preferably at least 30%, even more preferably at least 40%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100%, compared to untreated (non-immunized) subjects who are subsequently infected with a particular PEDV. It should therefore be understood that a subject can be vaccinated with the immunogenic composition of the present invention to reduce or prevent clinical signs (e.g. diarrhea or mortality). Preferably, the subject is a piglet, a pig or a sow. Furthermore, the present invention provides a method of inducing the production of antibodies specific for PEDV in a subject, said method comprising administering to said subject an immunogenic composition as described herein. Preferably, said subject is a piglet, a pig or a sow. Furthermore, the present invention provides a method for inducing the production of antibodies specific for PEDV in a sow, said method comprising the step of administering to said sow an immunogenic composition as described herein.
[0047] The term "antibody specific for PEDV" refers to detectable anti-PEDV antibody. Moreover, anti-PEDV antibody in sows has been developed in response to vaccination with the PEDV vaccine of the present invention. The term "antibody specific for PEDV" or "antibody specific for PEDV in sows" also refers (but is not limited to) to sows having a detectable anti-PEDV antibody titer, preferably at least 1:10, more preferably more than 1:20, more preferably more than 1:40, more preferably more than 1:80, more preferably more than 1:160, more preferably more than 1:320, and most preferably more than 1:640. Preferably, the anti-PEDV antibody titer can be detected and quantified with a specific anti-PEDV immunoassay. Advantageously, the immunogenic compositions of the present invention have been shown to induce the production of antibodies specific for PEDV in sows. It is well known to those skilled in the art how to detect the production of PEDV-specific antibodies, for example by ELISA assay (ELISAs are commercially available). Additionally, the present invention provides a method of reducing diarrhea in piglets compared to a non-immunized control group of piglets, the method comprising administering a therapeutically effective amount of an immunogenic composition as described herein to a sow of piglets, wherein the piglets are suckled by the sow. As used herein, the term "sow of piglets" should be understood to be equivalent to, among other things, a "mother sow of piglets" or a "foster sow of piglets", respectively. Additionally, the present invention provides a method of reducing mortality in piglets compared to a non-immunized control group of piglets, the method comprising administering a therapeutically effective amount of an immunogenic composition as described herein to a sow of piglets, wherein the piglets are suckled by the sow.
[0048] Additionally, the present invention provides a method of reducing or preventing clinical signs or disease caused by PEDV infection in a piglet, where the piglet is suckled by a sow that has been administered an immunogenic composition described herein. Preferably, the clinical sign that is reduced is mortality. Thus, the present invention also provides a method of reducing mortality caused by PEDV infection in piglets, the piglets being suckled by a sow that has been administered an immunogenic composition as described herein. Furthermore, the present invention provides a method for reducing or preventing clinical signs or disease caused by PEDV infection in a piglet, said method comprising the steps of: - administering an immunogenic composition as described herein to a sow; and - allowing the piglet to be suckled by the sow or allowing the piglet to drink milk from the sow, respectively. Advantageously, the immunogenic compositions of the present invention have been shown to reduce clinical signs in pigs when administered to pregnant sows. It must be understood that when vaccinating piglets with the immunogenic composition of the invention, time is required for the actual production of antibodies in the piglets. Therefore, in another aspect of the invention, a pregnant sow is vaccinated with the immunogenic composition of the invention. The vaccination results in the production of PEDV-specific antibodies in the sow. The maternal antibodies of the sow are then passively transferred to the newborn piglets via colostrum and / or milk.
[0049] In another particular feature of the method of the invention, the sow to which the immunogenic composition is administered is in particular a sow that is pregnant with piglets, however, it should be understood that the piglets may be suckled by any sow that provides colostrum or milk, but this sow is in particular the sow to which said immunogenic composition is administered. In another particular aspect, the method of the invention comprises the steps of: - administering an immunogenic composition as described herein to a sow that is pregnant with piglets, - allowing the sow to give birth to the piglet, - allowing the piglet to be suckled by the sow. In another specific feature of the method of the invention, the method results in an improvement in a clinical sign or efficacy parameter selected from the group consisting of: reduced weight loss, lower viral load, reduced diarrhea, reduced viral shedding, reduced rectal temperature, reduced mortality, reduced gross lesions in the intestine, or a combination thereof, compared to a non-immune control group of subjects of the same species. In another particular aspect of the method of the invention, the subject is a piglet, a pig or a sow. Preferably, the immunogenic composition is administered to the subject within the first two months of age, more preferably within the first month of age. In another particular aspect of the method of the invention, the immunogenic composition is administered to the subject within the first month of age. It should therefore be understood that the immunogenic composition may be administered to a subject, by way of example, within the first 3 weeks of age or within the first 2 weeks of age.
[0050] In another specific aspect of the method of the invention, the immunogenic composition of the invention is administered to pregnant and lactating sows. Advantageously, the immunogenic compositions of the present invention have been proven safe when administered to pregnant sows. Thus, there is provided a method of vaccinating pigs against PEDV by administering the PEDV vaccine of the present invention to a pregnant sow at least twice prior to farrowing, preferably at least three times prior to farrowing, more preferably twice prior to farrowing ("multiple doses"). Preferably, the pregnant sow is vaccinated twice with the PEDV vaccine of the present invention, with one dose of said vaccine prior to farrowing. However, when the vaccine is administered twice to the sow, the first administration should be performed between 12 and 4 weeks prior to farrowing, more preferably between 9 and 5 weeks prior to farrowing. The second administration should be performed between 8 and 1 week prior to farrowing, more preferably between 6 and 1 week prior to farrowing. In another specific aspect of the method of the invention, the immunogenic composition is administered in two or more doses. Advantageously, the immunogenic composition of the present invention has been shown to induce the production of antibodies specific for PEDV after two doses. In another particular aspect of the method of the invention, the immunogenic composition is administered twice to the sow, the first administration being between 9 and 5 weeks prior to farrowing and the second administration being between 6 and 1 week prior to farrowing.
[0051] The immunogenic composition is preferably administered locally or systemically. Commonly used suitable administration routes are oral or parenteral, such as intranasal, intravenous, intramuscular, intraperitoneal, subcutaneous, as well as inhalation. However, depending on the nature and mode of action of the compound, the immunogenic composition may be administered by other routes as well. However, most preferably, the immunogenic composition is administered intranasally or orally. In another specific aspect of the method of the invention, the immunogenic composition of the invention is administered intranasally, mucosally, orally, intradermally or intramuscularly. Advantageously, the immunogenic compositions of the present invention have been shown to be effective when administered intranasally. In another particular aspect of the method of the invention, the immunogenic composition of the invention is administered intranasally or orally.
[0052] Preferably, the immunogenic composition comprises 1x10 2 From 1x10 9 TCID 50 / mL, more preferably 1x10 3 From 1x10 7 TCID 50 / mL, most preferably 1x10 4 From 1x10 6 TCID 50 / mL. In another specific aspect of the method of the invention, the immunogenic composition comprises 1x10 3 From 1x10 7 TCID 50 / mL. "TCID 50 The term “infectious virus titer” refers to the degree of infectious virus titer. Specifically, the titer is the tissue culture infectious dose 50 (TCID 50 / mL) indicates the dilution of virus preparation that infects 50% of the number of cultured cells inoculated in parallel with that dilution. Another specific feature of the method of the invention results in a decrease in viral shedding from day 2 post challenge or infection. Another specific feature of the method of the invention results in a decrease in viral shedding from day 3 post challenge or infection. Another specific feature of the method of the invention results in a reduction in viral shedding from day 4 post challenge or infection. Another specific feature of the method of the invention results in a reduction in viral shedding from day 5 post challenge or infection. Another specific feature of the method of the invention results in a reduction in viral shedding from day 7 post challenge or infection. Another specific feature of the method of the invention results in a reduction in viral shedding from day 10 post challenge or infection. Another specific feature of the method of the invention results in a reduction in viral shedding from day 5, 7 or 10 post challenge or infection. Advantageously, the immunogenic compositions of the present invention have been demonstrated to reduce viral shedding following infection or challenge.
[0053] The term "reduced viral shedding" means that viral shedding is reduced by at least 10%, more preferably at least 20%, even more preferably at least 30%, even more preferably at least 40%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, even more preferably at least 95%, and most preferably 100%, compared to a non-treated (non-immunized) subject who is subsequently infected with a particular PEDV. How to measure viral shedding is within the general knowledge of a person skilled in the art. The term "viral shedding" refers to the secretion of PEDV in fecal excretion or feces. Thus, viral shedding can be determined by testing the viral titer in fecal excretion, feces or rectal swabs. The term "viral shedding" further encompasses the transmission of the virus to susceptible animals (i.e., sentinels). It is common knowledge of the skilled artisan how to measure viral shedding (e.g., PCR, qPCR or ELISA). In another particular aspect of the method of the invention, said method enhances protection against a homologous challenge. Advantageously, the immunogenic compositions of the invention are proven to be protective following challenge. The present invention provides the use of a nucleic acid molecule encoding the Porcine Epidemic Diarrhea Virus (PEDV) spike (S) protein, a PEDV (S) protein or an immunogenic composition as described herein for the manufacture of a medicament. The present invention also provides the use of a nucleic acid molecule encoding the porcine epidemic diarrhea virus (PEDV) spike (S) protein, a PEDV (S) protein or an immunogenic composition described herein for the treatment and / or prevention in a subject of clinical signs caused by PEDV infection, or the alleviation of diarrhea in a subject.
[0054] Overview of Arrays The following sequences are detailed and disclosed in the present invention herein: SEQ ID NO: 1: RSXIEDXX, SEQ ID NO:2: Wild type G2a PEDV S amino acid sequence US, SEQ ID NO:3: Wild type G2b PEDV S amino acid sequence EU, SEQ ID NO:4: RSXIEDLLF, SEQ ID NO:5: RSXIEDAAF, SEQ ID NO:6:XXXFXKXXXX, SEQ ID NO: 7: YXXFXKXH, SEQ ID NO:8: AXXFXKXR, SEQ ID NO: 9: PEDV S European strain genotype 2b (G2b) sequence with mutation 897A; SEQ ID NO: 10: PEDV S European strain genotype 2b (G2b) sequence with an A mutation at amino acid position 898; SEQ ID NO: 11: PEDV S European strain genotype 2b (G2b) sequence with mutations 897A and 898A; SEQ ID NO: 12: PEDV S European strain genotype 2b (G2b) sequence with the mutations 897A and 1374A and 1381A; SEQ ID NO: 13: PEDV S European strain genotype 2b (G2b) sequence with the mutations 898A and 1374A and 1381R; SEQ ID NO: 14: PEDV S European strain genotype 2b (G2b) sequence with the mutations 897A, 898A and 1374A and 1381R; SEQ ID NO: 15: PEDV SUS strain genotype 2a (G2a) sequence with mutation 900A; SEQ ID NO: 16: PEDV SUS strain genotype 2a (G2a) sequence with an A mutation at amino acid position 901; SEQ ID NO: 17: PEDV SUS strain genotype 2a (G2a) sequence with mutations 900A and 901A; SEQ ID NO: 18: PEDV SUS strain genotype 2a (G2a) sequence with mutations 900A and 1377A and 1384R; SEQ ID NO: 19: PEDV SUS strain genotype 2a (G2a) sequence with mutations 901A and 1377A and 1384R; SEQ ID NO: 20: PEDV SUS strain genotype 2a (G2a) sequence with mutations 900A, 901A and 1377A and 1384R; SEQ ID NO: 21: RSXIEDLX, SEQ ID NO: 22: RSXIEDXL, SEQ ID NO:23: RSXIEDLA, SEQ ID NO:24: RSXIEDAL, SEQ ID NO: 25: RSXIEDAA, SEQ ID NO: 26: XXXFXKXHXX, SEQ ID NO:27: YXXFXKXXXX, SEQ ID NO:28: AXXFXKXHXX, SEQ ID NO: 29: YXXFXKXRXX, SEQ ID NO: 30: AXXFXKXRXX, SEQ ID NO: 31: RSXIEDLG, SEQ ID NO:32: RSXIEDGL, SEQ ID NO: 33: RSXIEDGG, SEQ ID NO: 34: RSXIEDGA, SEQ ID NO: 35: RSXIEDAG, SEQ ID NO:36 contains a cloning cassette for the PEDV spike protein, the cassette containing a duplicated UTR region for the inserted gene; SEQ ID NO:37 (RNA) corresponds to the sequence encoding the S protein of SEQ ID NO:14; SEQ ID NO:38 (RNA) corresponds to a sequence including SEQ ID NO:37; SEQ ID NO: 39: Wild-type G2a PEDV S amino acid sequence, CN, SEQ ID NO: 40: PEDV SCN strain genotype 2a (G2a) with the mutations 900A, 901A and 1377A and 1384R; SEQ ID NOs:41-44: Probe, primer, and ultramer sequences (Table 2). In the sequence listing, the amino acid sequences are presented in three letter code with the symbol "Xaa" equivalent to the variable "X", and the phrase "residue X" provided in the sequence listing is equivalent to "residue Xaa".
[0055] item The following items are described herein: The present invention provides the following: 1. A nucleic acid molecule encoding a porcine epidemic diarrhea virus (PEDV) spike (S) protein comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO:1), (I) X2 is an amino acid residue other than a leucine residue and X3 is a leucine residue; or (II) X2 is a leucine residue and X3 is an amino acid residue other than a leucine residue; or (III) The nucleic acid molecule as described above, wherein X2 is an amino acid residue other than a leucine residue, and X3 is an amino acid residue other than a leucine residue. 2.- When the PEDV S protein is a genotype 2a (G2a) PEDV S protein and the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein, R is an arginine residue at amino acid position 894; or - When the PEDV protein is a genotype 2b (G2b) PEDV S protein and the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein, R is an arginine residue at amino acid position 891; 2. The nucleic acid molecule according to item 1, comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1). 3.- the amino acid sequence of the wild-type G2a PEDV S protein is the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO: 2 or SEQ ID NO: 39, and / or - the amino acid sequence of the wild-type G2b PEDV S protein is the amino acid sequence of the wild-type G2b PEDV S protein of SEQ ID NO: 3; Item 3. The nucleic acid molecule according to item 2. 4. A nucleic acid molecule encoding a porcine epidemic diarrhea virus (PEDV) spike (S) protein comprising the amino acid sequence RSX1IEDX2X3 (SEQ ID NO: 1), R is a conserved arginine residue at the S1 / S2 cleavage site of the PEDV S protein, and X1 can be any amino acid residue; and (I) X2 is an amino acid residue other than a leucine residue and X3 is a leucine residue; or (II) X2 is a leucine residue and X3 is an amino acid residue other than a leucine residue; or (III) The nucleic acid molecule, wherein X2 is an amino acid residue other than a leucine residue, and X3 is an amino acid residue other than a leucine residue. 5. A nucleic acid molecule encoding a porcine epidemic diarrhea virus (PEDV) spike (S) protein selected from the group consisting of (a) and (b): (a) a genotype 2a (G2a) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 900 is replaced by an amino acid residue other than leucine; and / or - the leucine residue at amino acid position 901 is replaced by an amino acid residue other than leucine; wherein the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO:2 or SEQ ID NO:39; (b) a genotype 2b (G2b) PEDV S protein having at least one mutation, - the leucine residue at amino acid position 897 is replaced by an amino acid residue other than leucine; and / or - the leucine residue at amino acid position 898 is replaced by an amino acid residue other than leucine; Here, the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein in SEQ ID NO:3. 6. The nucleic acid molecule according to any one of items 1 to 5, wherein the amino acid residue other than a leucine residue is selected from the group consisting of an alanine residue, a glycine residue, an isoleucine residue, a methionine residue and a valine residue. 7. The nucleic acid molecule according to any one of items 1 to 6, wherein the amino acid residue other than the leucine residue is an alanine residue. 8. The nucleic acid molecule according to any one of items 5 or 7, wherein the numbering of the amino acid positions refers to the amino acid sequence RSXIEDLLF (SEQ ID NO:4) of the wild-type G PEDV S protein, R is the conserved arginine residue of the S1 / S2 cleavage site of the PEDV S protein, and LL is amino acid positions 900 and 901 within the genotype 2a (G2a) PEDV S protein, or LL is amino acid positions 897 and 898 within the genotype 2b (G2b) PEDV S protein. 9. The nucleic acid molecule according to any one of items 5 to 8, wherein the numbering of the amino acid positions refers to the amino acid sequence RSXIEDLLF (SEQ ID NO:4) of the wild-type G PEDV S protein, and R is an arginine residue at amino acid position 894 and LL is amino acid positions 900 and 901 in the genotype 2a (G2a) PEDV S protein, or R is an arginine residue at amino acid position 891 and LL is amino acid positions 897 and 898 in the genotype 2b (G2b) PEDV S protein. 10. The nucleic acid molecule according to any one of items 1 to 9, wherein the PEDV S protein comprises the amino acid sequence RSXIEDAAF (SEQ ID NO:5), wherein R is a conserved arginine residue in the S1 / S2 cleavage site of the PEDV S protein, and AA is the amino acid positions 900 and 901 in a genotype 2a (G2a) PEDV S protein, or AA is the amino acid positions 897 and 898 in a genotype 2b (G2b) PEDV S protein. 11. The PEDV S protein comprises the amino acid sequence RSXIEDAAF (SEQ ID NO:5), wherein R is an arginine residue at amino acid position 894 and AA are amino acid positions 900 and 901 in a genotype 2a (G2a) PEDV S protein, or R is an arginine residue at amino acid position 891 and AA are amino acid positions 897 and 898 in a genotype 2b (G2b) PEDV S protein. 11. A nucleic acid molecule according to any one of items 1 to 10. 12. the PEDV S protein further comprises the amino acid sequence X1X2X3FX4KX5X6X7X8 (SEQ ID NO: 6), wherein X8 is the C-terminal amino acid residue of the PEDV S protein or is the amino acid residue at position -2 relative to the C-terminal amino acid position of the PEDV S protein; X2 to X5, X7 and X8 can be any amino acid residue; and (i) X1 is an amino acid residue other than a tyrosine residue and X6 is a histidine residue; or (ii) X1 is a tyrosine residue and X6 is an amino acid residue other than a histidine residue; or (iii) X1 is an amino acid residue other than a tyrosine residue, and X6 is an amino acid residue other than a histidine residue; 12. A nucleic acid molecule according to any one of items 1 to 11. 13.(a) G2a PEDV S protein further comprising: - the tyrosine residue at amino acid position 1377 is replaced by an amino acid residue other than a tyrosine residue, and / or the histidine residue at amino acid position 1384 is replaced by an amino acid residue other than a histidine residue, or (b) the G2b PEDV S protein further comprises - the tyrosine residue at amino acid position 1374 is replaced by an amino acid residue other than tyrosine, and / or - the histidine residue at amino acid position 1381 is replaced by an amino acid residue other than histidine, 14. A nucleic acid molecule according to any one of items 5 to 13. 14.- The amino acid residues other than tyrosine residues are selected from the group consisting of alanine, glycine, leucine, isoleucine, methionine and valine residues, and / or - the amino acid residue other than the histidine residue is an arginine residue, 14. A nucleic acid molecule according to items 12 to 13. 15.- The amino acid residue other than the tyrosine residue is an alanine residue, and / or 15. The nucleic acid molecule according to any one of items 12 to 14, wherein the amino acid residue other than the histidine residue is an arginine residue. 16. The nucleic acid molecule according to any one of items 13 to 15, wherein the numbering of the amino acid positions refers to the amino acid sequence YXXFXKXH (SEQ ID NO:7) of the wild-type G PEDV S protein, where Y and H are amino acid positions 1377 and 1384 within the genotype 2a (G2a) PEDV S protein, or Y and H are amino acid positions 1374 and 1381 within the genotype 2b (G2b) PEDV S protein. 17. The nucleic acid molecule according to any one of items 12 to 16, wherein the nucleic acid molecule comprises a sequence encoding the amino acid sequence AXXFXKXR (SEQ ID NO:8), wherein A and R are amino acid positions 1377 and 1384 within the genotype 2a (G2a) PEDV S protein, or wherein A and R are amino acid positions 1374 and 1381 within the genotype 2b (G2b) PEDV S protein. 18. PEDV S protein is i) (a) comprising or consisting of an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 15, 16, 17, 18, 19, 20, 40; or (b) comprising or consisting of an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 9, 10, 11, 12, 13, and 14; and / or ii) (a) is encoded by a nucleotide sequence encoding an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 15, 16, 17, 18, 19, 20, and 40; or (b) encoded by a nucleotide sequence encoding an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 9, 10, 11, 12, 13, and 14; 18. A nucleic acid molecule according to any one of items 1 to 17. 19. The PEDV S protein is (a) comprising any one of the amino acid sequences of SEQ ID NOs: 15, 16, 17, 18, 19, 20, and 40; or (b) comprising any one of the amino acid sequences of SEQ ID NOs: 9, 10, 11, 12, 13, and 14; 19. A nucleic acid molecule according to any one of items 1 to 18. 20. A PEDV(S) protein encoded by a nucleic acid molecule according to any one of items 1 to 19. 21. The nucleic acid molecule according to any of items 1 to 19 or the PEDV S protein according to item 20, wherein the nucleic acid molecule encoding the PEDV S protein or the PEDV S protein is recombinant. 22. A polynucleotide comprising a nucleic acid molecule according to any one of items 1 to 19. 23. A vector comprising a nucleic acid molecule according to any one of items 1 to 19 or a polynucleotide according to item 22. 24. The vector according to item 23, which is CDV, EHV, ORF virus, PRV, CAV, PCMV or BoHV-4. 25. The vector according to item 23, wherein the vector is CDV or EHV. 26. An immunogenic composition comprising a nucleic acid molecule encoding a PEDV S protein according to any one of items 1 to 19 and / or a PEDV S protein according to item 20 and / or a vector according to any one of items 23 to 25. 27. The immunogenic composition according to item 26, wherein the immunogenic composition further comprises a pharma- ceutically acceptable carrier. 28. The immunogenic composition according to item 26 or 27, wherein the immunogenic composition is a vaccine. 29. A cell comprising a nucleic acid molecule according to any one of items 1 to 19, a polynucleotide according to item 22, or a vector according to any one of items 23 to 25. 30. A method for producing a nucleic acid molecule encoding a PEDV S protein according to any one of items 1 to 19 and / or a PEDV S protein according to item 20, comprising a step of transfecting a cell with a vector according to any one of items 23 to 25. 31. A method for preparing an immunogenic composition for treating and / or preventing PEDV infection in a subject, comprising the steps of: a.) infecting a cell with a vector according to any one of items 23 to 25; b.) obtaining said vector; and c.) Adding a pharma- ceutically acceptable carrier. 32. The cell according to item 29 or the method according to item 30 or 31, which is a Vero cell, an ST cell or a BHK-21 cell, a Ma104 cell, an MDBK cell, a RK13 cell, an MDCK cell or a PK15 cell. 33. The immunogenic composition according to item 27 or the method according to item 31, wherein the pharma- ceutically acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, absorption delaying agents, adjuvants, immunostimulants, and combinations thereof. 34. A method for immunizing a subject, comprising administering to the subject an immunogenic composition according to any one of items 26 to 28. 35. The immunogenic composition according to any of items 26 to 28, for use in a method for immunizing a subject, comprising administering to the subject a therapeutically effective amount of the immunogenic composition. 36. A method for treating and / or preventing clinical signs caused by PEDV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an immunogenic composition described in any of items 26 to 28. 37. The immunogenic composition according to any one of items 26 to 28 for use in a method for treating and / or preventing clinical signs caused by PEDV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the immunogenic composition according to any one of items 26 to 28. 38. A method for reducing mortality in a subject compared to a non-immune control group of subjects of the same species, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to any one of items 26 to 28. 39. The immunogenic composition according to any of items 26 to 28 for use in a method for reducing mortality in a subject compared to a non-immune control group of subjects of the same species, comprising the step of administering to the subject a therapeutically effective amount of the immunogenic composition. 40. A method for inducing the production of PEDV-specific antibodies in a sow, comprising administering to the sow an immunogenic composition according to any one of items 26 to 28. 41. The immunogenic composition according to any one of items 26 to 28, for use in a method for inducing the production of PEDV-specific antibodies in a sow, comprising the step of administering a therapeutically effective amount of the immunogenic composition to the sow. 42. A method for reducing mortality in a piglet compared to a non-immunized control group of piglets, comprising administering a therapeutically effective amount of the immunogenic composition according to any one of items 26 to 28 to a sow of the piglet, wherein the piglet is suckled by the sow. 43. The immunogenic composition according to any one of items 26 to 28 for use in a method for reducing mortality in a piglet compared to a non-immunized control group of piglets, the method comprising administering a therapeutically effective amount of the immunogenic composition to a sow of the piglet, wherein the piglet is suckled by the sow. 44. A method for reducing or preventing clinical signs or disease caused by PEDV infection in a piglet, wherein the piglet is suckled by a sow that has been administered an immunogenic composition described in any of items 26 to 28. 45. An immunogenic composition according to any one of items 26 to 28, for use in a method for reducing or preventing clinical signs or disease caused by PEDV infection in a piglet, wherein the piglet is suckled by a sow that has been administered the immunogenic composition. 46. A method for reducing or preventing clinical signs or disease caused by PEDV infection in piglets, comprising the steps of: - administering an immunogenic composition according to any one of items 26 to 28 to a sow, and - allowing the piglet to be suckled by the sow. 47. An immunogenic composition according to any of items 26 to 28, for use in a method for reducing or preventing clinical signs or disease caused by PEDV infection in piglets, comprising: - administering the immunogenic composition to a sow; and - allowing a piglet to be suckled by said sow. 48. The method according to any of items 34 to 47, wherein the sow to which the immunogenic composition is administered is pregnant, in particular a sow pregnant with the piglet. 49. The method according to any one of items 34 and 46 to 48, comprising the steps of: - administering the immunogenic composition according to any one of items 26 to 28 to a sow pregnant with piglets, - allowing the sow to give birth to the piglet, - allowing the piglet to be suckled by the sow. 50. The method according to any one of items 36, 37, 40, 44, 45, 46, 47, 48 or 49, which results in an improvement in clinical signs or efficacy parameters selected from the group consisting of reduced weight loss, lower viral load, reduced diarrhea, reduced viral shedding, reduced rectal temperature, reduced mortality, reduced gross lesions in the intestine, or a combination thereof, compared to a non-immune control group of subjects of the same species. 51. The method according to any one of items 34 to 39, wherein the subject is a piglet, a pig or a sow. 52. The method according to any one of items 34 to 39 or 51, wherein the immunogenic composition is administered to the subject within the first month of age. 53. The method according to any of items 34 to 52, wherein the immunogenic composition is administered to pregnant and lactating sows. 54. The method according to any of items 34 to 53, wherein the immunogenic composition is administered in two or more doses. 55. The method according to any of items 34 to 44, wherein the immunogenic composition is administered twice to the sow, the first administration being between 9 and 5 weeks before farrowing and the second administration being between 6 and 1 week before farrowing. 56. The method according to any of items 34 to 55, wherein the immunogenic composition is administered intranasally, mucosally, orally, intradermally or intramuscularly. 57. The method according to any one of items 34 to 56, wherein the immunogenic composition is administered intranasally or orally. 58. The immunogenic composition comprises 1x10 of a vector, in particular according to any of items 23 to 25. 3 From 1x10 7 TCID 50 58. The method of any one of items 34 to 57, comprising: 59. The method according to any of items 34 to 5860, which results in reduced viral shedding at 5, 7 or 10 days post-challenge or infection. 60. The method of any of items 34 to 59, wherein the method enhances protection against a homologous challenge.
[0056] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following examples set forth the preferred materials and procedures of the present invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. However, it should be understood that these examples are provided merely as illustrative, and that none of them should be construed as limiting the overall scope of the invention. EXAMPLES
[0057] Preparation of spike modifications A) Expression of PEDV-S by recombinant CDV vectors In an in vitro experiment, a complete plasmid (pBR322) encoding the complete CDV genome derived from the Lederle vaccine strain (Lederle; ATCC VR-128) was digested with SacII endonuclease and subsequently cloned a PEDV spike (S) protein coding cassette between the P and M genes (resulting in a sequence containing SEQ ID NO: 36). Upon cloning and rescue of the recombinant CDV-PEDV-S, it was possible to show the expression of the porcine epidemic diarrhea virus spike protein of the 2b genotype in CDV-associated fluorescent foci. The respective results are also achieved for the corresponding CDV vectors (i.e., they only differ in the sequence encoding the porcine epidemic diarrhea virus spike protein of the 2a genotype SEQ ID NO: 20). The results obtained with both vectors by immunofluorescence show a strong PEDV spike protein expression in all CDV-infected syncytia (data not shown).
[0058] B) Preparation of EHV expressing the PEDV spike The synthetic sequences SEQ ID NO:3 and SEQ ID NO:14 were used to generate EHV1 recombinants expressing the spike proteins PEDV-S2b-wt and PEDV-S2b-mut, which were synthesized and subcloned into the transfer vectors pUC19-ORF1 / 3-PEDV-S2b-wt and pUC19-ORF1 / 3-PEDV-S2b-mut, respectively. The expression cassettes of PEDV-S2b-wt or PEDV-S2b-mut were inserted into the orf1 / 3 region of pRacH-SE by en passant mutagenesis using the RED recombination system (Tischer et al. 2006), generating the final BAC DNAs pRacH-SE-PEDV-S2b-wt and pRacH-SE-PEDV-S2b-mut. The resulting BAC DNA was transfected into RK13 cells, and the recombinant virus rEHV-1 was rescued and plaque purified. Correct insertion of the expression cassette was confirmed by sequencing the product of high-fidelity PCR of the insertion region. Expression of the transgene in infected cells was analyzed and confirmed by indirect immunofluorescence assay (IFA) (data not shown). Furthermore, the virus was passaged for 20 cell passages in RK13 cells to confirm the in vitro stability of the construct. EXAMPLES
[0059] Localization of spikes in the plasma membrane An EHV-1 recombinant vector encoding the wild-type (naturally occurring) PEDV-S protein of the 2b genotype (EHV1-PEDV-S2b-wt) was compared with an EHV-1 recombinant encoding a mutated spike protein (mutations at amino acid positions 897 / 898 / 1374 / 1381 (SEQ ID NO: 14) and designated EHV1-PEDV-S2b-mut). Briefly, RK13 cells were plated at 2x10 per well of a 6-well plate. 5Cells were plated in 6-well cell culture plates at a density of 1000 x 1000 cells / well. The following day (24 h after seeding), cells were infected with either EHV1-PEDV-S2b-wt or EHV1-PEDV-S2b-mut at an MOI of 0.01. Two days (48 h) after infection, cells were fixed with 3% paraformaldehyde solution for 1 h. Fixed cell monolayers were permeabilized with 0.1% Tween 20, followed by staining of cells with mouse anti-PEDV monoclonal antibody clone 7D7_G1 (Abpro-Labs 2.4.16) (1:200 dilution in PBS). After 1 h, cells were washed twice with room temperature PBS (1000 μL / well). 750 μL of a 1:500 dilution of commercial secondary antibody (goat anti-mouse-FITC (Life Technology cat:A11029 lot:1705900)) was added and incubated in the dark (protected from light) for 60 min. After incubation, the secondary antibody solution was aspirated by vacuum, followed by washing the cells twice with room temperature PBS (1000 μL / well). Results were obtained using an Olympus inverted fluorescence microscope (mod.IX81) with a FITC filter to detect the specific fluorescence of PEDV spike protein in cells (Figure 1). The spike protein expressed from the EHV1-PEDV-S2b-wt recombinant vector was mainly localized in the cytoplasm, whereas the spike protein expressed from EHV1-PEDV-S2b-mut was mainly localized in the membrane of the cells. EXAMPLES
[0060] Growth kinetics of Vero cells Preface Efficient propagation of recombinant viral vectors is one of the essential features for efficient production of vaccines. Canine distemper virus (CDV) vaccines are produced in Vero cells (ATCC™ CCL-81 TM ) most often produced using a roller bottle production system. We compared the growth kinetics of two CDV recombinants: (i) a CDV backbone derived from the Lederle vaccine strain (see Example 1) having an insertion of SEQ ID NO:39 (encoding the PEDV spike protein of SEQ ID NO:20) between the P and M genes, referred to herein as "CDV-PEDV-spike-MUT" or "CDV-PEDV-spike mut"; and (ii) The respective vectors encoding the corresponding wild-type protein (PEDV spike protein of SEQ ID NO:2), referred to herein as "CDV-PEDV-spike-WT" or "CDV-PEDV-spike wt." Experimental setup : Roller bottle (490cm 3 ) 2x10 7 Vero cells were seeded with 10 ... CDV titration protocol material : -Cells: VeroDogSLAM BI (6x10) seeded 24 hours prior in a 96-well plate 3 cells / well) -Culture solution: MEM (SAFC, SLBX3503) - 48-well plate for dilution production : - Use 48-well plates for dilutions, - Fill the wells with 1080 μL of MEM, - Pipette 120 μL of each sample into the first column, -Mixing program, 10 of each sample -1 From 10 -8 Make a 10-fold dilution of - Use one well plate for each dilution, - Transfer dilutions onto pre-seeded cells (100 μL / well), -Create 8x replicates of each sample; Incubate in a cell incubator at -37°C for 3 days. -Read using a microscope by detecting typical CDV syncytium formation in the cells. Results and Discussion The CDV-PEDV-spike-MUT recombinant showed higher infectious virus titers at days 1, 2, 3, 4, 5, and 6 post-infection of Vero cells. Furthermore, although both recombinants reached peak supernatant titers at day 4 post-infection, the CDV-PEDV-spike-MUT reached a two-fold higher infectious titer than the CDV-PEDV-spike-WT recombinant (see FIG. 2), indicating the benefit of the spike mutation on CDV vector fitness. The virus titers of all these cell-free supernatants were measured, and based on empirical data (data not shown), the titers of the cellular fraction were at least 100-fold higher, and therefore in a production set-up (where roller bottles are harvested containing the cellular fraction), the difference in titers between the two recombinants is expected to be proportionately greater. EXAMPLES
[0061] Vaccine animal data Vaccine Efficacy Testing Porcine epidemic diarrhea (PED) is a highly contagious swine disease that can have a significant economic impact. All age classes of pigs are susceptible to infection, but severe clinical signs and mortality are mainly observed in suckling piglets. The causative agent is the PED virus (PEDV), an enveloped, single-stranded, positive-stranded RNA virus of the genus Alphacoronavirus in the family Coronaviridae. In Europe, PEDV first appeared in the UK in the late 1970s. It then spread throughout Europe causing sporadic outbreaks. In the late 1990s, PEDV disappeared from European pig farms as evidenced by very low seroprevalence and no disease reports. Outbreaks and endemic infections are still reported from Asia, where the disease has a major impact on the productivity of industrialized pig farms. Beginning in 2005, PED cases were reported again from Europe. Following the introduction of an apparently highly virulent form of PEDV into the United States in 2013, cases were also reported from Central Europe (including Germany and neighboring countries). The latter cases were caused by a related but distinct PEDV strain (the so-called S-INDEL strain). In Germany, cases have been reported since May 2014, showing high morbidity and variable mortality in suckling pigs. In this study, a CDV backbone derived from the Lederle vaccine strain (see Example 1) with an insertion of the sequence of SEQ ID NO:37 (encoding the PEDV spike protein) between the P and M genes was tested as a vector vaccine (referred to in the following text as "CDV_PEDV-Spike vaccine" or "CDV PEDV-Spike vector vaccine", respectively) in six sows and their offspring. All animals were checked for PEDV by RT-qPCR targeting the S gene and a PEDV-specific antibody. Only negative animals were enrolled in the study. Animals were randomly assigned to three treatment groups (see below): Group 1 (negative control): 2 sows (designated #1 and #2), non-vaccinated; Group 2 (positive control): 2 sows (designated #3 and #4), non-vaccinated; Group 3 (CDV_PEDV-Spike): 2 sows (designated #5 and #6), vaccinated with the CDV_PEDV-Spike vector vaccine. Vaccination of two sows in group 3 was performed according to the following schedule, with the stock titer of CDV_PEDV-Spike vaccine being 7.94x10 4 The TCID50 / mL (defined by end point quantification): 9 weeks before expected farrowing date: 4 mL of vaccine administered intranasally to each of 2 sows (2 mL in each nostril); 6 weeks before expected farrowing date: 4 mL of vaccine administered intranasally to each of 2 sows (2 mL in each nostril); Three weeks prior to expected farrowing date: Each of two sows is given 4 mL of the respective vaccine intranasally (2 mL in each nostril) and an additional 2 mL intramuscularly. Piglets born to sows in group 1 (13 piglets from sow #1 and 12 piglets from sow #2) were orally mock-inoculated. Piglets born to sows in group 2 (12 piglets from sow #3 and 14 piglets from sow #4) and piglets born to sows in group 3 (5 piglets from sow #5 and 15 piglets from sow #6) were orally challenged at 4 days of age with a PEDV field strain (referred to in the following text as “PEDV EU”). Cell culture adapted PEDV EU was used for inoculation of piglets in groups 2 and 3. The titer was 2.15x10 5 The TCID50 / mL was used. Piglets in groups 2 and 3 were orally inoculated. In this case, each piglet received 1 mL of a 1:10 dilution of virus stock (titer 2.15x10 4 TCID50) was administered using a 2 mL syringe. Piglets in group 1 were sham-inoculated orally with 1 mL of cell culture medium in a 2 mL syringe. During the entire study, rectal swabs (CPPAN plain swabs without media) were taken from all animals on the day of inoculation and days 1 to 10 post-inoculation (pi) as well as on days 14, 17 and 20 / 21 pi for RT-qPCR. Additional rectal swabs were taken from four piglets of each sow pre-inoculation and 2 days post-challenge for bacteriological testing. Furthermore, clinical signs indicative of PED were scored daily using an established standardized cumulative scoring system (see below). Blood samples were taken on the day of inoculation and 14 and 20 / 21 pi (end of study) or on the day of euthanasia or death of each animal.
[0062] Clinical monitoring An established cumulative clinical score was used for daily monitoring of clinical signs indicative of PED (see table below). TIFF0007587612000001.tif104149 Table 1: Cumulative clinical scores for clinical signs indicative of PED.
[0063] Sample preparation and nucleic acid extraction Rectal swabs were immersed in 1 mL of Dulbecco's Modified Eagle Medium and incubated at room temperature for 1 h. Viral RNA was extracted using either the QIAmp Viral RNA Mini Kit (Qiagen) or the NucleoMagVet-Kit with the KingFisher extraction platform. RNA was stored at -20°C until further use. Blood samples were centrifuged at 2031xg for 20 minutes at room temperature to obtain serum, which was then aliquoted and stored at -20°C. Virus detection To detect PEDV shedding, a RT-qPCR system targeting the S gene of PEDV was used as previously described (Stadler et al., BMC Vet Res. 11:142, 2015). Samples taken from 0 to 7 dpi and at 10 and 20 / 21 dpi (days after challenge virus inoculation) were tested for PEDV genome. Genome copy amount / μL was calculated using an in-house standard. Antibody detection A commercial indirect ELISA (INgezim PEDV, INGENASA, Madrid, Spain) was performed on all sera according to the manufacturer's manual. bacteriology Faeces of four piglets per litter were collected at 0 and 2 dpi for differential bacteriology. statistics The Shapiro-Wilk test was used to test for normality, and the Mann-Whitney rank sum test was performed as provided in the software package. Statistical significance was tested using SigmaPlot software.
[0064] result Antibody detection in serum : All piglets in the CDV group showed positive results in ELISA (detecting antibodies against the PEDV spike protein) prior to challenge due to the ingestion of seropositive colostrum, whereas all animals in the positive and negative control groups showed clearly negative results. At 14 dpi, all (except for the three piglets in the positive control group) had seroconverted, while all animals in the vaccine group still showed high amounts of PEDV-specific IgG in serum samples. At the end of the study, all piglets in the CDV and positive control groups showed strongly positive ELISA results. None of the negative control animals seroconverted throughout the entire study. In further trials, it was also observed that similar antibody results were achieved when sows alone were vaccinated twice via the intranasal route. bacteriology : Fecal swabs taken at 0 and 2 dpi did not show any pathogenic bacteria. The bacterial flora did not undergo significant changes upon infection. Clinical signs : Piglets in the positive control group (group 2) showed clear clinical signs indicative of PEDV over a 7-day period, beginning with vomiting at 24 hpi followed by diarrhea. Eight of 26 piglets had to be euthanized due to severe dehydration and clinical scores above 6 (humane endpoint). The first clinical signs indicative of PEDV were detectable at 36 hpi. Overall, the clinical signs of piglets vaccinated with the CDV vector and challenged with PEDV (group 3) were better in terms of systemic responses, with only 2 out of 20 pigs (10%) in group 3 having to be euthanized due to severe dehydration and clinical scores above 6 (compared to 31% of piglets in group 2). Negative control animals remained healthy throughout the entire study. Viral shedding : Clear differences in virus shedding could be detected between the challenged groups: at 1 dpi, all challenged piglets were positive for viral genomes in rectal swabs, but animals in the CDV-PEDV vaccinated group had significantly lower genome copy numbers than animals in the challenged group (mean Ct value 26.65). Furthermore, over the next 5 days, the genome load in rectal swabs of the CDV group was quite similar to the positive controls, but starting at 7 dpi the detectable amount of viral genome fell below the cut-off level in piglets protected by vaccinated sows, whereas all animals in the positive control group still shed PEDV. The PEDV genome was not detectable at all in swabs from the negative control group. In conclusion, the results of this study showed that piglets born to sows vaccinated with the CDV PEDV-Spike recombinant vaccine showed reduced clinical signs compared to the positive control, with particularly large improvements observed in terms of piglet mortality / mortality. Furthermore, viral shedding after PEDV challenge was significantly reduced. Furthermore, animal studies corresponding to the vaccine efficacy studies described above have been performed in which two doses (5 weeks and 2 weeks prior to farrowing) of a CDV backbone derived from the Lederle vaccine strain carrying an insert between the P and M genes encoding the PEDV spike protein of SEQ ID NO:40 (see Example 1) are administered and challenged with a more highly virulent genotype 2a PEDV field strain. Piglets born to sows vaccinated with this recombinant vaccine show reduced mortality or reduced clinical signs compared to challenge controls. EXAMPLES
[0065] In this animal study, a CDV backbone derived from the Lederle vaccine strain carrying an insert between the P and M genes encoding the PEDV spike protein of SEQ ID NO:20 (see Examples 1 and 4) was tested as a vector vaccine (referred to in the following text as "CDV_PEDV-G2a vaccine" or "CDV PEDV-G2a Spike vector vaccine", respectively) in 20 sows and their offspring. Only animals deemed negative by qRT-PCR and ELISA were enrolled in the study. Animals were randomly assigned to three treatment groups (see below): Group 1 (strict negative control): 2 sows (designated 1- and 4), non-vaccinated; Group 2 (challenge control): 8 sows (designated 5-12), non-vaccinated; Group 3 (CDV_PEDV-G2a-Spike): 8 sows (designated 13-20), vaccinated with the CDV_PEDV-G2a-Spike vector vaccine. Vaccination of eight sows in group 3 was performed 5 weeks (D0) and 2 weeks (D21) before farrowing of the study, while the stock titer of CDV_PEDV-G2a Spike vaccine was 2.57x10 5 The TCID50 / mL was determined by end point titration. For each vaccination, sows received 4 mL of vaccine intranasally (2 mL in each nostril). Piglets born to sows in group 1 (total of 41 piglets) were not challenged (strict control). Piglets born to sows in group 2 (total of 81 piglets) and piglets born to sows in group 3 (total of 83 piglets) were challenged with a highly virulent PEDV field strain (belonging to the G2a genotype) at 2.0 x 10 3 They were orally challenged at 3-7 days of age with a dose of TCID50 / 2mL dose (1mL intranasally + 1mL orally). Throughout the study, rectal swabs were taken the day before inoculation and on days 1, 3, 7, and 14 pi (post challenge virus). Sample preparation and nucleic acid extraction Rectal swabs were submerged in 2 mL of Minimum Essential Medium (MEM) at the time of collection and stored at -70°C prior to processing. Samples were processed by vortexing for 10 seconds followed by centrifugation at 1,500xg for 10 minutes at 4°C. After processing, 100 μL / sample was used for virus extraction using the BioSprint One-For-All Vet Kit (Qiagen) on a BS96 Vet 100 BioSprint extraction platform. RNA was stored at -20°C until further use. Blood samples were centrifuged at 1960xg for 10 minutes at room temperature to obtain serum, which was then divided into aliquots and stored at -70°C. Virus detection To detect PEDV shedding, an in-house developed RT-qPCR system targeting the S gene of PEDV was used: a quantitative one-step RT-PCR kit (iTaq Universal One-Step RT-PCR kit; BioRad, cat no. 1725140) was used for the assay. Real-time RT-PCR was performed in a 25 μL reaction containing: 2 μL of extracted total nucleic acid, 0.75 μL of probe (4 μM), 0.5 μL of each primer (10 μM), 12.5 μL of 2X RT-PCR mix, 0.5 μL of iScript reverse transcriptase, and 8.25 μL of DEPC-treated water. See Table 2 below for primer, probe, and ultramer sequences. Reactions were performed using a CFX96 Real-Time Detection System (Biorad) with the following conditions: initial reverse transcription at 50°C for 30 min, followed by initial denaturation at 95°C for 5 min, annealing and extension at 95°C for 15 s and 57°C for 30 s for 40 cycles. To obtain quantitative data, PEDV Ultramer (Integrated DNA Technologies) was incorporated into each reaction. Lyophilized Ultramer (4 nmol) was resuspended in DEPC-treated, nuclease-free sterile water to create a stock concentration of 1.0E+10 genome copies / μL (gc / μL). From the stock Ultramer, 10-fold serial dilutions were made in DEPC-treated water from 1.0E+08 to 1.0E+01. This concentration was confirmed prior to use by Qubit dsDNA HS assay. Optical data were analyzed using the CFX Manager software. For each determination, a threshold line was automatically calculated using the regression settings for cycle threshold (Ct) determination mode. The baseline was subtracted automatically using the baseline subtraction mode. Curves with baseline end values below 10 were manually corrected. TIFF0007587612000002.tif57168 Table 2: Probe (Pr), primers (F / R) and ultramer sequences used in the internal induction RT-qPCR system.
[0066] Antibody detection An in-house developed CCIF assay was used to test serum and milk samples from this study: Wild-type PEDV isolates (genogroup 2a) were diluted 1:100 in PEDV growth medium (MEM + 2.5% HEPES + 0.3% tryptose phosphate broth + 0.02% yeast + 10 μg / mL trypsin). Diluted virus (100 μL / well) was inoculated into 2-day-old 96-well plates plated with VERO cells. Prior to infection, cell growth medium was removed from the plates and the plates were washed twice with 100 μL PEDV growth medium. Plates were incubated for 24 hours at 37 ± 2°C + CO2 (4-6%). After incubation, the supernatant was discarded and the plates were washed twice with 200 μL / well 1X PBS. For fixation, ethanol (200 μL / well) was added. Plates were incubated at room temperature for 30 minutes, air-dried, and stored at -20°C until use. Prior to use in the assay, plates were rehydrated with 200 μL / well of 1X PBS (Gibco) for 10 min at room temperature and blocked with 100 μL / well of buffer (1X PBS + 1% normal goat serum + 0.1% Triton X) for 15 min at room temperature. Serial two-fold dilutions of serum samples were prepared in dilution buffer (1X PBS + 5% BSA + 1% normal goat serum + 0.1% Triton X) containing PEDV Mab antibody (Median diagnostics) at a 1:1000 dilution. Diluted samples (50 μL / well) were added to the prepared plates and incubated at 37°C for 1 h. After incubation, plates were washed three times with 1X PBS (200 μL / well). A total of 50 μL / well of diluted secondary antibodies [Alexa594 goat anti-mouse IgG (Fisher; 1:500 dilution); FITC-labeled goat anti-pig IgG (BioRad; 1:500 dilution); Hoechst 33342 (Fisher; 1:1000 dilution)] were then added to each plate and incubated for 1 h at 37°C. After incubation, the plates were washed three times with 1X PBS (200 μL / well). Fluorescence was observed. PEDV-infected cells bound by Mab3F12 showed a specific red color. Colocalization of green fluorescence was an indication of porcine IgG binding. The highest dilution at which specific green fluorescence was observed was equivalent to the IgG titer. result mortality rate : In group 1 (strict control), 40 pigs survived, in group 2 (challenge control), 16 pigs survived, and in group 3 (CDV-PEDV-G2a spike vaccinated) 34 pigs survived, resulting in mean mortality rates of 2% (group 1), 80% (group 2), and 59% (group 3), respectively. Antibody response : The specific PEDV antibody response after challenge demonstrated that the arithmetic mean levels of CCIF IgG antibody titers in serum and milk of sows were higher in the CDV-PEDV-G2a spiked vaccinated group than in group 2 (challenge control). This indicates that vaccinated sows responded strongly by boosting IgG levels in milk and serum after infection with virus from infected piglets after challenge. In comparison, antibody titers in challenge control sows (antibody titers due to PEDV infection simply through contact with challenged piglets (and their feces)) were significantly lower. Viral shedding At day 3 post-challenge virus inoculation, similar arithmetic mean RNA loads were detected in the vaccinated and non-vaccinated groups, respectively, reaching 9.2 and 9.8 group arithmetic mean log10 PEDV genome copies in the CDV-PED-G2a spiked vaccinated and challenge control groups, respectively. At D48 (7 dpi) and D55 (14 dpi), the arithmetic mean log10 PEDV genome copy numbers in the CDV-PEDV-G2a spiked vaccinated group were 3.2 and 2.0 log10, respectively, whereas in the challenge control group they were 5.5 and 3.9 log10, respectively, showing a 2.3 and 1.9 log reduction at 7 dpi and 14 dpi, respectively. Although longer-term shedding monitoring was not performed, the trends in viral shedding kinetics observed at days 7 and 14 post-challenge virus inoculation indicate a shortened duration of viral shedding in vaccinated animals, consistent with the results described above in Example 4. No PEDV genome was detectable in swabs from the strict negative control group. In conclusion, the results of this study were that piglets born or suckled from sows vaccinated with the CDV PEDV-G2a spike recombinant vaccine, respectively, showed a significant reduction in mortality when challenged with a highly virulent PEDV strain compared to piglets in the control group. Furthermore, these piglets, which acquired PEDV protective IgG antibodies from milk (through transfer of maternal antibodies in the early days after birth), showed a significant reduction in virus shedding after challenge at 7 and 14 days post-infection, which is an important epidemiological parameter.
Claims
1. A nucleic acid molecule encoding a porcine epidemic diarrhea virus (PEDV) spike (S) protein selected from the group consisting of (a) and (b) below, excluding the S protein having the amino acid sequence of SEQ ID NO:14: (a) a genotype 2a (G2a) PEDV S protein having the following mutations: - the leucine residue at amino acid position 900 is replaced by an alanine residue, - the leucine residue at amino acid position 901 is replaced by an alanine residue, - the tyrosine residue at amino acid position 1377 is replaced by an alanine residue, and - the histidine residue at amino acid position 1384 is replaced by an arginine residue, wherein the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2a PEDV S protein of SEQ ID NO:2 or SEQ ID NO:39; and (b) a genotype 2b (G2b) PEDV S protein having the following mutations: - the leucine residue at amino acid position 897 is replaced by an alanine residue, - the leucine residue at amino acid position 898 is replaced by an alanine residue, - the tyrosine residue at amino acid position 1374 is replaced by an alanine residue, and - the histidine residue at amino acid position 1381 is replaced by an arginine residue, Here, the numbering of the amino acid positions refers to the amino acid sequence of the wild-type G2b PEDV S protein in SEQ ID NO:
3.
2. A PEDV S protein encoded by the nucleic acid molecule of claim 1.
3. A nucleic acid molecule described in claim 1 or a PEDV S protein described in claim 2, which is recombinant.
4. A vector comprising the nucleic acid molecule of claim 1.
5. An immunogenic composition comprising a nucleic acid molecule encoding the PEDV S protein of claim 1 and / or the PEDV S protein of claim 2 and / or the vector of claim 4.
6. The immunogenic composition of claim 5 for use in a method for immunizing a subject, the method comprising administering a therapeutically effective amount of the immunogenic composition to a subject.
7. The immunogenic composition of claim 5 for use in a method for reducing or preventing clinical signs or disease caused by PEDV infection in piglets, wherein the piglets are suckled by a sow to which the immunogenic composition has been administered.
8. The immunogenic composition of claim 5 for use in a method for reducing mortality caused by PEDV infection in piglets, wherein the piglets are suckled by a sow to which the immunogenic composition has been administered.
9. The immunogenic composition of any one of claims 6 to 8, which is administered intranasally, mucosally, orally, intradermally or intramuscularly.
Citation Information
Patent Citations
Porcine epidemic diarrhea virus strain MY01 and application thereof
CN105462936A
Porcine epizootic diarrhea virus strain and vaccine composition, preparation method and application thereof
CN106148287A
swine epidemic diarrhea virus vaccine
JP2017511328A
Coronavirus proteins and antigens
US20160339097A1
